

**DISSERTATION FOR THE DEGREE OF DOCTOR OF PHILOSOPHY
(PHD)**

**Immunogenicity of vaccines in rheumatoid arthritis and
COVID-19**

by Éva Rákóczi

**UNIVERSITY OF DEBRECEN
DOCTORAL SCHOOL OF CLINICAL MEDICINE
DEBRECEN, 2024**

DISSERTATION FOR THE DEGREE OF DOCTOR OF PHILOSOPHY
(PHD)

**Immunogenicity of vaccines in rheumatoid arthritis and
COVID-19**

by Éva Rákóczi MD

Supervisor: Prof. Zoltán Szekanecz MD, PhD, DSc



UNIVERSITY OF DEBRECEN
DOCTORAL SCHOOL OF CLINICAL MEDICINE
DEBRECEN, 2024

Contents

1. INTRODUCTION	7
1.1. THE IMPORTANCE OF PNEUMOCOCCAL VACCINATION.....	7
1.2. THE COVID-19 PANDEMIC.....	8
2. LITERATURE REVIEW.....	9
2.1. LOWER RESPIRATORY TRACT INFECTIONS IN AIRD	9
2.2. BIOLOGIC THERAPY OF RA	9
2.3. PNEUMOCOCCAL VACCINATION	10
2.3.1. <i>Pneumococcal virulence factors: the capsular polysaccharide</i>	10
2.3.2. <i>Pneumococcal vaccine developments</i>	11
2.3.3. <i>Different pneumococcal vaccines: different immunogenicity</i>	12
2.3.4. <i>Pneumococcal vaccination - general considerations and sequential scheme</i>	13
2.3.5. <i>Conjugate pneumococcal vaccination with PCV in AIRD patients treated with biologics: missing data</i>	14
2.4. EFFICACY OF THE THIRD COVID-19 VACCINATION.....	15
2.4.1. <i>Short review about coronaviruses</i>	15
2.4.2. <i>COVID vaccination: the first messenger ribonucleic acid vaccine</i>	15
2.4.3. <i>Hungarian vaccination protocol for citizens</i>	16
2.4.4. <i>Third vaccination of COVID-19</i>	16
3. OBJECTIVES, SPECIFIC AIMS	19
4. PATIENTS AND METHODS	20
4.1. STUDY I.	20
4.1.1. <i>Study population and epidemiological data</i>	20
4.1.2. <i>Vaccination of patients</i>	22
4.1.3. <i>Laboratory methods</i>	22
4.1.4. <i>Safety assessments</i>	22
4.1.5. <i>Statistical analysis</i>	23
4.2. STUDY II.	23
4.2.1. <i>Study population and epidemiological data</i>	23
4.2.2. <i>Vaccination of patients</i>	24
4.2.3. <i>Laboratory methods</i>	26
4.2.4. <i>Statistical analysis</i>	26
5. RESULTS	27
5.1. STUDY I.	27
5.1.1. <i>Antibody response to PCV-13 vaccine</i>	27
5.1.2. <i>Subgroup analysis: treatment with or without MTX</i>	28
5.1.3. <i>Correlations between change of IgG and epidemiological data</i>	29
5.1.4. <i>Vaccine safety and side effects</i>	30
5.1.5. <i>Predictive factors and antibody response in RA patients</i>	32
5.1.6. <i>Practical recommendations of pneumococcal vaccination in RA patients</i>	33
5.2. STUDY II.	34
5.2.1. <i>Antibody response in heterologous and homologous vaccination groups</i>	34
5.2.2. <i>Age-related subgroup analysis of SARS-CoV-2 total Ig levels</i>	36
5.2.3. <i>Time-related analysis of SARS-CoV-2 total Ig levels after the third-dose vaccination</i>	38
5.2.4. <i>Vaccine safety and side effects</i>	39
6. DISCUSSION	40
6.1. STUDY I.	40
6.1.1. <i>Studies of PPV-23 in RA patients treated with biologics</i>	40
6.1.2. <i>Studies of PCV in RA patients treated with biologics</i>	41

6.1.3. Concomitant immunosuppressive treatment affecting antibody response: MTX	42
6.1.4. Concomitant immunosuppressive treatment affecting antibody response: corticosteroids.....	43
6.1.5. Older age as a predictive factor for antibody response	43
6.1.6. Limitations of the study	44
6.2. STUDY II.....	44
6.2.1. The effect of third-dose BNT62b2 vaccination on the heterologous (BBIBP-CorV) and homologous (BNT162b2) groups	44
6.2.2. Strengths and limitations of the study	46
7. SUMMARY	47
7.1. STUDY I.	47
7.2. STUDY II.	48
8. ÖSSZEFOGLALÁS (SUMMARY IN HUNGARIAN)	49
8.1. TANULMÁNY I.	49
8.2. TANULMÁNY II.	50
9. REFERENCES	51
9.1. REFERENCES OF DISSERTATION.....	51
9.2. LIST OF OWN PUBLICATIONS	59
10. KEYWORDS - TÁRGYSZAVAK.....	67
11. ACKNOWLEDGEMENTS	68
12. APPENDIX	69

List of abbreviations

AAAI	:	American Academy of Allergy, Asthma & Immunology
ACIP	:	Advisory Committee on Immunization Practices
ACR	:	American College of Rheumatology
ADAb	:	anti-drug antibody
AE	:	adverse event
AIR	:	adequate immune response
AIRD	:	autoimmune rheumatic diseases
Anti-CCP	:	anti-cyclic citrullinated peptide
CAP	:	community acquired pneumonia
COVID-19	:	coronavirus disease 2019
CRP	:	C-reactive protein
DAS-28	:	disease activity score (28-joint)
DMARD	:	disease-modifying antirheumatic drug
ELISA	:	enzyme-linked immunosorbent assay
EMA	:	European Medicines Agency
ETA	:	etanercept
EU	:	European Union
EUA	:	Emergency Use Authorization
EULAR	:	European League Against Rheumatism
hACE2	:	human Angiotensin-Converting Enzyme 2
HIV	:	Human Immunodeficiency Virus
IDSA	:	Infectious Diseases Society of America
IG	:	immunoglobulin
IGG	:	immunoglobulin G
IPD	:	Invasive pneumococcal disease
MG	:	milligram
mRNA	:	messenger ribonucleic acid
MTX	:	methotrexate
NSAID	:	non-steroidal anti-inflammatory drug
HPH	:	The Hungarian Public Health Centre
OA	:	osteoarthritis
PCV	:	protein-conjugated pneumococcal vaccine
PCV-7	:	7-valent pneumococcal conjugated vaccine
PCV-10	:	10-valent pneumococcal conjugated vaccine
PCV-13	:	13-valent pneumococcal conjugated vaccine
PPV	:	polysaccharide pneumococcal vaccine
PPV-23	:	23-valent pneumococcal polysaccharide vaccine
PY	:	person-years
RA	:	rheumatoid arthritis
SARS	:	Severe Acute Respiratory Syndrome
SARS-CoV-2	:	Severe Acute Respiratory Syndrome Coronavirus-2
SC	:	subcutaneously

SD : standard deviation
SOT : solid organ transplantation
S1-RBD : spike protein 1 receptor-binding domain
TNF- α : tumor necrosis factor α
VS : versus
WHO : World Health Organization

List of tables

- Table 1.** Timeline of pneumococcal vaccine development (Page 11)
- Table 2.** Pneumococcal vaccines and serotypes (Page 12)
- Table 3.** Sequential pneumococcal vaccination scheme in pneumococcal vaccine-naïve and vaccinated patients (Page 14)
- Table 4.** Epidemiological data of studied patients (Study I.) (Page 21)
- Table 5.** Epidemiological data of studied patients (Study II.) (Page 24)
- Table 6.** Serum pneumococcal antibody level at baseline, after one and two months (Page 27)
- Table 7.** The effect of etanercept-methotrexate combination vs etanercept monotherapy on antibody response (Page 28)
- Table 8.** Spearman's correlation analysis of the RA group (Page 30)
- Table 9.** Treatment follow-up after vaccination in study group (Page 31)
- Table 10/a.** Follow-up of RA subgroup treated with corticosteroids 1. (Page 31)
- Table 10/b.** Follow-up of RA subgroup treated with corticosteroids 2. (Page 32)
- Table 11.** Univariate logistic regression estimates of the effects of various factors on the odds of inadequate immune response in RA group (after 1 and 2 months of vaccination) (Page 32)
- Table 12.** Checklist for optimal decision making in management of pneumococcal vaccination in RA patients (Page 33)

List of figures

- Figure 1.** Study design of COVID vaccination (basic and third) in two groups and blood sampling (Page 25)
- Figure 2.** Pneumococcal antibody levels at baseline (IgG 0) and one month (IgG 1) and two months (IgG 2) after vaccination (Page 28)
- Figure 3.** Correlation between age and rate of changes of pneumococcal antibody IgG levels (IgG 2/IgG 0) in RA patients (Page 30)
- Figure 4.** Anti-SARS-CoV-2 total Ig levels before and after the third dose of BNT162b2 vaccination in BBIBP-CorV and BNT162b2 groups (Page 35)
- Figure 5.** Ratio of total Ig levels (after/before ratio of third dose of BNT162b2 vaccine) between BBIBP-CorV and BNT162b2 groups (Page 36)
- Figure 6.** Age-related effect on anti-SARS-CoV-2 S1-RBD total Ig titers within 2 cohorts before and after the third-dose vaccination (Page 37)
- Figure 7.** Correlation of Timing of second and third dose of vaccine and antibody responses (Page 38)

1. Introduction

1.1. The importance of pneumococcal vaccination

In 2015, lower respiratory tract infections affected 3.2 million people, these infections were on the third place on the “top 10 causes of death” list published by the World Health Organization (WHO) [1]. The position of these infections has not changed between 2000 and 2015; as the number of affected people (3.4 versus 3.2 million) decreased by only 200000. The annual incidence of community acquired pneumonia (CAP) in the general adult population is between 1.6 and 13.4 cases per 1000 inhabitants [2].

The most common pathogen of community and hospital acquired pneumonia is *Streptococcus pneumoniae* (pneumococcus). A European systematic review showed that pneumococcus was the most common isolated pathogen between 1990 and 2007 with variable incidence (11.9% - 68.3%) and mortality (1 - 48%) in different countries [3]. During seasonal and pandemic influenza, the leading cause of death is bacterial pneumonia caused by pneumococcus [4]. Due to its resistance to antibiotics, treatment is more and more difficult and challenging.

Risk factors for pneumococcal pneumonia include older age, chronic medical conditions including diabetes mellitus, chronic liver and renal failure, pulmonary asthma, as well as secondary immunodeficiency including splenectomy, gravidity, hemato-oncological disorders, organ transplant, Human Immunodeficiency Virus (HIV) infection, and autoimmune rheumatic diseases (AIRD) [5].

Pneumococcal vaccines are crucial in preventing severe pneumococcal disease. For vulnerable populations, such as the elderly, individuals with certain health conditions, pneumococcal vaccination is particularly important as they are at higher risk of developing severe complications from pneumococcal infections. The diverse recommendations encompass factors like age groups, risk categories, types of vaccines, vaccination schedules (including single or sequential vaccinations), and reimbursement policies. Such variations can result in complexities for healthcare providers and patients alike. Therefore, comprehensive evidence becomes crucial to streamline recommendations and optimize vaccination strategies.

1.2. The COVID-19 pandemic

The first confirmed case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in humans can be traced back to November 17, 2019, in China. On December 31, 2019, the Chinese Health Authority informed the WHO about 41 individuals who exhibited pneumonia of unknown origin. Most of these patients had visited the Huanan seafood market, which was subsequently closed the following day [6]. On January 7, 2020, Chinese researchers identified the pathogen causing the pneumonia, revealing it to be a new type of coronavirus responsible for the infection [7]. January 11, 2020, marked the world's first acknowledgment of a fatality due to the novel coronavirus infection, and on the same day, Chinese researchers identified the genetic makeup of the virus [8].

SARS-CoV-2 primarily targets the respiratory system, binding to the human Angiotensin-Converting Enzyme 2 (hACE2) receptors found on mucosal cells within the airways. The interaction between the receptor-binding domains (RBDs) of the spike proteins and hACE2 can result in various pathological consequences, which vary among patients. Based on current research and clinical observations, the infection can manifest symptoms of varying severity. In some cases, individuals may experience mild symptoms, such as fever, cough, fatigue, and loss of taste or smell. Others might develop moderate symptoms involving difficulty breathing, chest pain, and persistent fever. Severe cases can lead to acute respiratory distress syndrome (ARDS), pneumonia, organ failure, and in some instances, death. The severity and specific symptoms experienced by individuals often depend on various factors, including the patient's overall health, age, and any underlying medical conditions. Understanding these different levels of disease severity is crucial for appropriate medical management and intervention strategies [8].

The SARS-CoV-2 pandemic has affected millions of lives globally and a significant number of lives lost. As of August 2022 over 6.4 million people has died of a total of 608 million infected patients [9]. These numbers highlight the severity of the pandemic and the importance of global efforts to address and mitigate its effects. As we continue to navigate this situation, it's crucial to prioritize safety measures, vaccination, and healthcare support to minimize further spread and loss of life.

While specific antiviral therapies for SARS-CoV-2 continue to be researched and developed, vaccination remains a key strategy in building immunity against the virus and curbing its spread within communities. It's vital to encourage widespread vaccination to protect individuals and collectively strive for herd immunity.

2. Literature review

2.1. Lower respiratory tract infections in AIRD

The group of AIRD involves; among others, rheumatoid arthritis (RA), idiopathic inflammatory myopathies, Sjögren's syndrome, systemic lupus erythematosus (SLE), systemic sclerosis and mixed connective tissue disease. Patients with AIRD are more vulnerable to infections due to their underlying disease and immunosuppressive therapy, compared to the general population. For example, in patients suffering from SLE, bacterial infections are commonly reported to affect diverse organs, including the respiratory tract [10], and the most common cause of death in those patients is infection [11].

Falagas et al [12] reported in their systematic review that patients with connective tissue disease had serious infections (bacteraemia and pneumonia), leading to death in 24% of the cases. Another cohort analysis showed that AIRD patients were more likely to be admitted to hospital for pneumococcal disease (rates for RA: 2.47; Sjögren's syndrome: 3.2; systemic sclerosis: 4.2; SLE: 5.0) compared to control cohorts [13].

The mortality of respiratory infections in RA patients corrected for age and gender is 2-5-times higher than that in the general population. Hospital admissions of patients with RA were doubled due to the severity of infections [14, 15]. In the general population, the annual incidence of CAP is 1.07-1.20/1000 person-years (PY) and the incidence among patients with AIRD treated with tumor necrosis factor α (TNF- α) inhibitors is 5.97/1000 PY [14, 15].

2.2. Biologic therapy of RA

RA is the classical example of AIRD. RA has a prevalence of 0.5-1% [16]. Disease-modifying antirheumatic drugs (DMARDs) decrease the progression of inflammation and joint destruction, and improve physical function in RA. DMARDs include conventional, synthetic (csDMARD), biologic (bDMARD) and targeted synthetic (tsDMARD) compounds. Methotrexate (MTX) is the most used csDMARD. Based on recent guidelines, the standard therapy has been replaced by early, aggressive DMARD therapy. Targeted therapies have been introduced for the treatment of RA in the early 2000s. Biologics have significantly changed the outcome of RA, improved physical function and quality of life of the patients. These therapies also decrease the risk of chronic comorbidities and organ complications [17, 18].

By 2006, the number of bDMARD-treated Hungarian patients increased to 900. In 2016, approximately 5000 patients were treated with biologics. In Europe, the rate of RA patients treated with biologics was 12.5 % in 2013, while in Hungary it was 9 % [19-21].

Biologics interfere with several inflammatory pathways. Most of the available bDMARDs suppress pro-inflammatory cytokines, primarily tumour necrosis factor α (TNF- α) and interleukin 6 (IL-6). Some biologics also inhibit B- and T-cells [17, 20, 22].

Immunogenicity of biologics is an important issue when we deal with vaccination of AIRD patients. Neutralizing anti-drug antibodies (ADAbs) to biologics are produced in 10-15% of treated patients [23-25]. ADAbs forms immune complexes resulting in increased hepatic clearance of biologics. The increased clearance leads to decreased plasma level of drugs, loss of main effects of biologics and development of side effects. The production of ADAbs has been observed in the case of anti-TNF- α antibodies such as infliximab, adalimumab, golimumab and certolizumab pegol. The soluble TNF receptor etanercept (ETA) is less immunogenic. Conventional DMARDs primarily MTX, combined with biologics decrease ADAbs production, resulting in a better and sustained efficacy [23-25].

2.3. Pneumococcal vaccination

2.3.1. Pneumococcal virulence factors: the capsular polysaccharide

Pneumococcus is a Gram-positive bacterium, a common commensal inhabitant of the nasopharynx. Colonization of the nasopharynx by pneumococcus is asymptomatic, and starts during infancy [26], with a prevalence of 40-95%, persisting at 1-10% in adulthood [27].

Nasopharyngeal carriage is a special step along the path of pneumococcal disease. Nasopharyngeal colonization is the main primary reservoir for transmission of pneumococcus causing infection [28]. Pneumococcus can spread by direct extension causing otitis media, sinusitis, and pneumonia. The most common other conditions via hematogenous spread are invasive pneumococcal disease (IPD), meningitis and pneumonia. Pneumococcus has many virulence factors, including capsular polysaccharides, pneumolysin, pneumococcal surface protein A, C and pneumococcal surface Adhesin A. The essential virulence factors of pneumococcus, which are responsible for severe invasive infections, are capsular polysaccharides [27]. Out of more than 90 serotypes of capsular polysaccharide, there are only 25-30 serotypes responsible for pneumococcal infections [29]. Geographic region, age, chronic diseases and use of antibiotics are the most common specific factors that determine the prevalence of pneumococcal serotypes [30].

2.3.2. Pneumococcal vaccine developments

While pneumococcal capsular polysaccharides play the most important role in the pathogenesis of the given disease, they are also a target for vaccine development. The aim of pneumococcal vaccine design is to cover the most common serotypes associated with severe disease and ensure effective long-term immunogenicity [29].

Two types of pneumococcal vaccines; namely, polysaccharide (PPV) and protein conjugated (PCV) pneumococcal vaccines have been developed. PPV was introduced first in 1977 with 14 serotypes, which was expanded to 23 in 1983 (Table 1) [29].

Table 1. Timeline of pneumococcal vaccine development*

1911	Starting pneumococcal vaccine research development
1915–1945	Description of structure of pathogen, virulence factors, antigenicity, serotypes. In 1940 were known more than 80 serotypes.
1977	Introduction of polysaccharide pneumococcal vaccine with 14 serotypes in the US
1983	Introduction of polysaccharide pneumococcal vaccine with 23 serotypes
2000	First development of conjugated pneumococcal vaccine with 7 serotypes
2009	Introduction of conjugated pneumococcal vaccine with 10 serotypes approved by European Commission
2010	Introduction of conjugated pneumococcal vaccine with 13 serotypes for children (6 weeks-71 months)
December 2011	First application of conjugated pneumococcal vaccine with 13 serotypes in adults ≥ 50 years
June 2012	ACIP recommendation of conjugated pneumococcal vaccine with 13 serotypes for adults aged ≥ 19 years with immunocompromising conditions
January 2013	Conjugated pneumococcal vaccine with 13 serotypes for teenagers (6–17 years)
July 2013	EMA recommendation of conjugated pneumococcal vaccine with 13 serotypes for all ages
Oct 2013	IDSA Clinical Practice Guideline for vaccination of the immunocompromised host including pneumococcal vaccination

*The table shows introductions of all pneumococcal vaccines from 1911 to 2013, approval of PCV-13 vaccine for all ages, and special patient groups.

2.3.4. Pneumococcal vaccination - general considerations and sequential scheme

There are three main aspects of vaccination that play a vital role in the protection of the population against pneumococcal infection:

1. Herd immunity
2. To cover the most common pathogen-related serotypes of vaccine
3. Good immunogenicity of vaccine

The incidence of serious invasive pneumococcal infection in the adult population can be modified by childhood vaccination. The good pneumococcal vaccination coverage in children can reduce transmission of the infection to adult contacts [39]. The so-called herd immunity occurs when unimmunized individuals get into contact with immunized ones. In this situation, there is a lower chance of infection by the organism. Except for some European countries (Bosnia and Herzegovina, Estonia, Montenegro), most countries in Europe have created, and regularly use recommendations on immunizations for pneumococcal disease within their childhood vaccination schedule [39]. In Hungary PCV-13 had been included in the mandatory childhood schedule since 2014 [40]. Serious invasive pneumococcal infections have been significantly reduced in children because of PCV administration in childhood [41]. As has been detailed in the previous section, PCV-13 has a higher immunogenicity than PPV-23, inducing T-cell-mediated B-cell memory [36].

The latest vaccination recommendations for adult based on systematic review and comprehensive field synopsis has been developed [42]. Based on the more evident immunogenicity of PCV-13, two studies confirmed immunological advantage in vaccine-naïve individuals if PCV-13 was given first, followed by PPV-23 [43]. T-cell-dependent immunogenicity of PCV-13 and coverage of 23-serotype PPV sequential pneumococcal vaccination sequential vaccination has to be applied. Based on the immunization history (previously PPV-23 vaccinated or not) of the patient suggested sequential pneumococcal vaccination scheme is recommended as seen on Table 3 [43, 44].

In 2012, ACIP recommended PCV-13 for adults aged ≥ 19 years with immunocompromised conditions [44]. Unfortunately, there are limited data available about the immunogenicity and safety of PCV-13 administered in that special fragile group of immunocompromised patients [44].

Bhorat et al [45] evaluated effectiveness of PCV-13 administered to HIV-infected patients. The phase 3, open-label, single-arm study including 151 HIV patients showed significant increase of antibody levels after the first dose of PCV-13 [45]. Patients suffering from chronic lymphocytic leukaemia without anticancer therapy responded with twofold increase in specific pneumococcal antibody level to PCV-13 thirty days after the vaccination [46].

PCV-7 was licenced only for children until 2009. The immunogenicity of PCV-7 in RA patients treated with biologic therapy was investigated and published between 2011 and 2015. [47-50]. Results showed that protective antibody response was impaired by rituximab and abatacept [50], anti-TNF- α with concomitant MTX [47] or corticosteroid treatments [48], smoking [49] and older age [50]. Even though several observational studies were published about the safety and immunogenicity of PPV-23 vaccination administered in AIRD patients treated with biologics (detailed in discussion), there has been no published data about the newly recommended PCV-13 vaccine in that group treated with biologics.

Table 3. Sequential pneumococcal vaccination scheme in pneumococcal vaccine-naïve and vaccinated patients

Pneumococcal vaccine (PPV-23) – naïve patient				
1st vaccine	Interval	2nd vaccine	Interval	3rd vaccine
PVC-13	> 8 weeks	PPV-23	> 5 years or > 65-year-old age	PPV-23
Previously PPV-23-vaccinated patient, aged < 65 years				
1st vaccine	Interval	2nd vaccine	Interval	3rd vaccine
PPV-23	> 1 year	PCV-13	> 8 weeks	PPV-23 (> 5 year after the 1 st PPV-23 vaccine)
Previously PPV-23- vaccinated patient, aged \geq 65 years				
1st vaccine	Interval	2nd vaccine		
PPV-23	> 1 year	PCV-13	-	-

2.3.5. Conjugate pneumococcal vaccination with PCV in AIRD patients treated with biologics: missing data

Even though several observations studies were published about the safety and immunogenicity of PPV-23 vaccination administered in AIRD patients treated with biologics (detailed in discussion), there has been no published data about the newly recommended PCV-13 vaccine in that group treated with biologics.

2.4. Efficacy of the third COVID-19 vaccination

2.4.1. Short review about coronaviruses

The term 'coronavirus' originates from the Latin word 'corona,' referring to the virus's morphology. It was first used in 1968. Prior to 2003, only two coronaviruses were known, causing mild illnesses in humans. However, the severe acute respiratory syndrome (SARS) virus emerged from Guangdong province in South China in 2003, infecting 8,000 people by July and resulting in 774 deaths. The Middle East Respiratory Syndrome virus, which is less contagious, emerged in Saudi Arabia in 2012, resulting in a higher death toll, claiming 866 lives out of nearly 2,500 cases [6-8].

In 2019, the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged from Wuhan, China, causing the most severe global pandemic of coronavirus to date. All three viruses share characteristics such as having a spherical virion with a single-stranded ribonucleic acid inside, surrounded by a lipid envelope with spike proteins on its surface. The spike protein acts as a multifunctional mechanism, regulating the virus's entry into the targeted host cell [51].

2.4.2. COVID vaccination: the first messenger ribonucleic acid vaccine

Traditional vaccine development often involves growing and inactivating a virus or using a weakened form of it, which can be time-consuming and challenging [52]. In contrast, messenger ribonucleic acid (mRNA) vaccines can be designed and produced relatively quickly once the genetic sequence of a virus is known. While mRNA vaccines had been studied for other diseases, the urgency of the pandemic accelerated their development and brought them to the forefront of public attention. The successful application of mRNA as a vaccine agent has brought about a revolution in vaccine development, especially highlighted by the rapid development of mRNA-based COVID-19 vaccines. The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was one of the first to receive Emergency Use Authorization (EUA), initially for individuals 16 years and older, and later expanded to include adolescents aged 12 through 15. This authorization was granted after rigorous evaluation of available data from clinical trials, which demonstrated the vaccine's safety and efficacy in preventing COVID-19 [53].

2.4.3. Hungarian vaccination protocol for citizens

For instance, if a particular vaccine like BNT162b2 was not universally accessible, Hungary might have opted to administer alternative vaccines to ensure continued vaccination efforts and protection against COVID-19 [54]. The Hungarian Public Health Centre (NPH) guide prioritized four groups targeting those most in need or with heightened exposure included (I.) healthcare workers; (II.) high risk patients (elderly patients and people with chronic comorbidities); (III.) individuals in critical infrastructure roles, ensuring the functioning of essential services and maintaining societal stability (e.g., education); and (IV.) covers those who don't fall into the previous categories, focusing on the broader population aged 18-59 who are not included in the higher priority groups [55].

In Hungary, the second available anti-SARS-CoV-2 vaccine was the BBIBP-CorV inactivated vaccine after the BNT162b2 mRNA vaccine; therefore the second risk group was immunized by the largest quantity of the BBIBP-CorV vaccine. Based on early studies that did not involve individuals over 65 and the latest clinical findings indicating decreased effectiveness of this vaccine in this age group, the anticipation for the use of heterologous boosters (utilizing different vaccines for the initial and subsequent booster doses in a vaccination regimen) suggests an interest in exploring whether combining different types of vaccines for initial and booster shots could provide additional benefits in terms of immunity and protection against COVID-19.

2.4.4. Third vaccination of COVID-19

The introduction of a third dose of COVID-19 vaccination during the third wave of the COVID-19 pandemic in 2021 was a response to emerging data on waning immunity and the need for additional protection, especially against new variants and potential breakthrough infections. The introduction of third dose was a part of the broader strategy to adapt vaccination campaigns in response to the changing nature of the virus and the dynamics of the pandemic, aiming to maintain high levels of protection and reduce the impact of COVID-19 [56, 57].

The need for further research and clinical data in this area underscored the importance of ongoing studies to determine the efficacy, safety, and immune response elicited by mixed vaccine schedules.

This information was vital for optimizing vaccination approaches, especially when considering third doses, and ensuring broad and robust protection against COVID-19 across different demographic groups. The comparison between BNT162b2 and BBIBP-CorV vaccines regarding their efficacy has been a focus of some studies [58, 59]. These studies suggested that BNT162b2 might offer higher efficacy in terms of raising antibody titres compared to BBIBP-CorV [58, 59].

Therefore, it becomes crucial to ascertain whether using a third dose of BNT162b2 after the initial BBIBP-CorV doses or vice versa could effectively improve the humoral immune response against the virus. According to the latest information, there's limited clinical data specifically addressing the efficacy and safety of using a combination of the BBIBP-CorV inactivated vaccine and the BNT162b2 mRNA vaccine as a third dose in non-Caucasian populations [59-63].

It seems that the heterologous approach, using the BNT162b2 mRNA vaccine as a third dose after an initial BBIBP-CorV inactivated vaccine regimen with a temporal separation, resulted in notable improvements in anti-spike antibody production. This suggests that combining these vaccines in this manner could lead to a more robust immune response compared to using either no third dose or a homologous regimen (receiving another dose of BBIBP-CorV) [60, 62, 63].

Clinical laboratory tests have indeed played a crucial role during the COVID-19 pandemic, especially in assessing the humoral response post-vaccination across various vaccine types. These tests help measure antibody levels and evaluate the effectiveness of vaccines in generating an immune response against SARS-CoV-2 [64]. Clinical studies have looked at the serological (antibody-related) responses in different populations under various conditions. These studies compare the immune responses in individuals who received different types of vaccinations - either as primary doses or third shots - and also consider whether these individuals had previous SARS-CoV-2 infections [65, 66].

The study by Pascuale et al [67] seems quite extensive, involving over 1300 participants and assessing 15 different combinations of vaccines. Their focus on evaluating the anti-spike IgG response and virus neutralizing titres is crucial in understanding the immune response generated by various vaccine combinations [67].

There have been limited trials or studies assessing the use of different vaccine combinations involving BBIBP-CorV. This vaccine has been used in a restricted number of countries, with limited data available from these specific regions [57, 58, 66]. The original phase I/II trial for BBIBP-CorV demonstrated efficacy in the 18–59-year-old age group [67–70]. Having this initial confirmation of efficacy in a specific age range is an important step in establishing the effectiveness of a vaccine. The lack of specific data on efficacy among the elderly might result in cautious recommendations regarding the use of BBIBP-CorV in this age group until more evidence becomes available to support its effectiveness and safety for older individuals [68, 71]. The comparative data highlighting lower efficacy and faster waning of effectiveness for BBIBP-CorV in comparison to vaccines like BNT162b2, mRNA1273 and Ad26.COVS underscores the differences observed among various COVID-19 vaccines [58, 72, 73]. The study by Blanco et al [73] indicating a significantly lower neutralizing response when BBIBP-CorV was used as a second dose in comparison to other protocols, is crucial in understanding the dynamics of mixed vaccine schedules. Their suggestion against recommending BBIBP-CorV as a second dose aligns with their findings regarding the diminished neutralizing response [73].

3. Objectives, specific aims

Study I.

Patients suffering from autoimmune rheumatologic diseases (AIRD) are at risk of acquiring respiratory infections, because of their immunocompromised status. The most common respiratory pathogen in community acquired pneumonia is *Streptococcus pneumoniae*. It is therefore advantageous for such patients to receive pneumococcal vaccines. However, administration of biologic therapy can modify the immune response to the vaccine. We therefore wanted to explore the effectiveness of such vaccines in patients with RA treated with biologic therapy.

Specific aims:

1. We aimed to investigate whether the 13-valent conjugated pneumococcal vaccine, Prevenar 13 (PCV-13) administered to rheumatoid arthritis (RA) patients treated with biologic therapy is effective.
2. The PCV-13 vaccine had been investigated in the general population, however, there has been little amount of safety data gathered in RA patients treated with biologics. Therefore our research investigated whether the PCV-13 vaccine was safe in RA patients undergoing biologic therapy with etanercept (ETA).
3. Based on our results we aimed to compile a set of recommendations for pneumococcal vaccination in RA patients.

Study II.

Specific aims:

1. We aimed to compare immunization regimens of homologous (2 basic and third dose of BNT162b2) and heterologous (2 basic BBIBP-CorV vaccines and third dose of BNT162b2 vaccine) COVID vaccination schemes.
2. We investigate whether a third dose of BNT162b2 administered after two doses of BBIBP-CorV effectively boosts anti-SARS-CoV-2 RBD humoral immune responses more than a homologous regimen of three BNT162b2 doses.
3. We investigate immune responses through subgroup analysis how different age groups react to vaccines.

4. We investigate if heterologous regimen of COVID vaccination is effective and safe.

4. Patients and methods

4.1. Study I.

4.1.1. Study population and epidemiological data

The study was a prospective observational study evaluated in patients who presented to the University of Debrecen Clinical Centre, Department of Internal Medicine, Division of Rheumatology. The study group included 22 adult patients with an established diagnosis of RA according to the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria [74]. All patients received ETA biological therapy. We included a control group of 24 patients with osteoarthritis. Patients with primary immunodeficiency and secondary immunodeficiency (e.g. chronic alcohol intake, bronchial asthma, chronic hepatitis, diabetes mellitus, malignancy, splenectomy or other AIRD) that may influence the antibody response to vaccination were excluded. The plasma immunoglobulin G, A and M levels of all participants were in a normal range. None of the patients showed signs of infection (at least 2 weeks prior to vaccination). All participants in the study and control groups were naive to pneumococcal vaccine. An Institutional Review Board approval had been obtained before the initiation of the study. All enrolled patients gave written consent for participation.

Table 4 presents the epidemiological characteristics of the individuals of study and control groups. Most of the RA patients were female (n=17; 77%) with mean age of 55.1±10.4 years; 5 male enrolled RA patients (23%) of the study group were younger than female patients with a mean age of 52±11.07 years. The control group of 24 patients with OA included 18 females and 6 males (mean age 63.9±9.7 years). There were no significant differences with respect to male: female ratio between the study and control group. Cardiovascular diseases (coronary heart disease, hypertension) were more common in the control group than in RA patients (88% vs 55%, p=0.034). The incidence of metabolic (hyperlipidaemia, obesity) and gastrointestinal (duodenal ulcer, gastro-oesophageal reflux) co-morbidities did not differ significantly between the two groups (p=0.46; p=0.403).

Immuno-laboratory tests revealed IgM rheumatoid factor seropositivity in 13 RA patients (59%) and anti-cyclic citrullinated peptide (anti-CCP) seropositivity in 11 RA

patients (50%). All enrolled RA patients had low disease activity as defined by EULAR [75] before vaccination. The mean DAS28-CRP value at baseline was 2.78 ± 0.62 . OA patients were taking non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics only, no patient was treated with any type of immunosuppressive drugs.

Table 4. Epidemiological data of studied patients (Study I.)

	RA group	Control group	p
All patients (n)	22	24	
Male	5	6	0.918
Female	17	18	
Mean age (year)	55.14±10.35	63.92±9.75	0.005
Male	52±11,07	61.33±12.47	0.226
Female	56.06±10.29	64.78±8.94	0.011
Comorbidities (n)			
Cardiovascular	12 (55 %)	20 (83 %)	0.034
Metabolic	6 (27%)	9 (36 %)	0.460
Gastrointestinal	8 (36%)	6 (24 %)	0.403
Treatment (n)			
Etanercept + MTX	15 (68 %)	0	-
Etanercept monotherapy	7 (32 %)	0	-
Without corticosteroid	17 (77 %)	24	-
Combined with corticosteroid	5 (23 %)	0	-
Immunolaboratory tests			
Rheumatoid factor positive	13 (59 %)	0	-
Anti-CCP positive	11 (50 %)	0	-
Disease activity			-
Mean DAS28-CRP	2.78±0.62	-	-

All RA patients were treated with 50 mg ETA administered subcutaneously (SC) once a week for at least one year. Out of these 22 RA patients, 15 patients (68%) received combination therapy of ETA plus oral MTX; 7 patients (32%) received ETA monotherapy. In patients treated with ETA+MTX combination, the mean MTX dose was 12.3±4.5 mg/week. In the RA group, five patients (23%) received oral corticosteroids. The mean corticosteroid dose was 2.8 ±1.1 mg/day. No DMARDs other than ETA and MTX were administered to the RA patients.

4.1.2. Vaccination of patients

PCV-13 vaccination was applied to all RA patients 5 days before administering the next dose of ETA. The vaccination was performed after obtaining written informed consent and after fulfilling the contraindication checklist (fever, signs and symptoms of infection). All subjects were vaccinated with a single dose (0.5 ml) of the PCV-13 vaccine (Prevenar 13, Pfizer™) IM into the upper arm.

4.1.3. Laboratory methods

Blood samples were collected by venepuncture and allowed to clot naturally. Serum samples were separated for the following tests: total anti-PPV23 antibody levels produced against the various serotypes at baseline before vaccination, 30 than 60 days after vaccination. All serum samples were stored at -70°C until the time of specific pneumococcal antibody level analysis. Pre-vaccination anti-PPV23 levels were compared to those 4 weeks and 8 weeks after vaccination. Pneumococcal antibody levels were assessed by a VaccZyme™ Anti-PCP IgG (immunoglobulin G) Enzyme Immunoassay Kit (produced by The Binding Site Group Ltd., Birmingham, United Kingdom). This specific assay is designed for the *in vitro* measurement of IgA antibodies against Pneumococcal Capsular Polysaccharide present in human serum. According to the recommendations of the American Academy of Allergy, Asthma & Immunology, at least a twofold increase in antibody level was an indicator of an adequate immune response (AIR) [76].

4.1.4. Safety assessments

All vaccinated patients were observed for 30 minutes after vaccination to ensure if there were any need for urgent medical attention following vaccination due to serious allergic

reaction (generalized rash, angioedema, anaphylaxis). After the observation period, asymptomatic and complaint-free patients were discharged and asked to record the temperature (feverish, fever), any injection site reactions (e.g. pain, redness, swelling), any adverse event (fatigue, nausea, vomiting, diarrhoea, myalgia, headache) or any other unusual events until the next follow-up visit (30 days after vaccination).

4.1.5. Statistical analysis

All statistical analyses were performed using the Statistical Package for the Social Sciences (IBM SPSS Statistics v20), USA. Categorical variables are reported as counts (percentages) and continuous variables as mean and standard deviation (SD). The distribution of continuous variables was evaluated by the Kolmogorov-Smirnov test. Data obtained in the RA and control groups were compared by independent samples t-test, Mann-Whitney U test, χ^2 test or Fisher's exact test. Changes of IgG levels were evaluated by Wilcoxon test separately in patients and control group. Correlations were determined by Spearman's test. Regression analysis was used to determine the relation between the change of IgG level and epidemiological data as prognostic factors. The used p-value threshold for significance was a two-sided value of 0.05 in all statistical tests.

4.2. Study II.

4.2.1. Study population and epidemiological data

This prospective observational study with 122 participants all together compared the antibody response for third dose of BNT162b2 vaccine after two, basically different COVID vaccine in two groups of 61 patients each. Both group was vaccinated by basic COVID vaccination; the first group by BBIBP-CorV and the second group by BNT162b2.

Adult patients (≥ 18 years) with primary immunodeficiency, or those undergoing immunosuppressive therapy, or with malignancy were excluded. None of the patients showed signs and symptoms of COVID-19 at least one week before third-dose vaccine. During the study patients with any suspicion of infection were monitored and tested by SARS-CoV-2 PCR.

Table 5. shows the demographic data of patients with comorbidities. In our provided data, while the mean ages of the two groups were close (the first group: 63.9 ± 12.61 years, the second group: 59.9 ± 12.92 years) there was a statistically non-significant difference ($p = 0.090$) between them. In the first group, there were 39 female patients, constituting 62.9% of that group, while the second group had 41 female patients, comprising 67.2% of that group. The p-value of 0.849 indicates that there was no statistically significant difference in gender distribution between the two groups.

The prevalence of various comorbidities was comparable between the two groups in the study. For instance, diabetes mellitus was the most common comorbidity in both groups had similar proportions: 21.3% in the study group and 16.4% in the control group, with a p-value of 0.643, indicating no statistically significant difference. Additionally, other comorbidities such as cardiovascular disease, autoimmune diseases, chronic respiratory diseases, chronic renal insufficiency didn't show significant differences in prevalence between the study cohorts.

Table 5. Epidemiological data of studied patients (Study II.)

	All patients	BBIBP-CorV group	BNT162b2 group	p
All patients (n)	122	61	61	
Age [year] [mean (SD)]	61.9 (12.87)	63.9 (12.61)	59.9 (12.92)	0.090
Genders [female (%)]	80 (65.6)	39 (62.9)	41 (67.2)	0.849
Co-morbidities [n (%)]	90 (73.8)	45 (73.8)	45 (73.8)	~ 1.0
Cardiovascular [n (%)]	86 (70.5)	43 (70.5)	43 (70.5)	~ 1.0
Autoimmune [n (%)]	18 (14.8)	9 (14.8)	9 (14.8)	~ 1.0
Respiratory [n (%)]	13 (10.7)	7 (11.5)	6 (9.8)	~ 1.0
Renal [n (%)]	6 (4.9)	3 (4.9)	3 (4.9)	~ 1.0
Diabetes mellitus [n (%)]	23 (18.9)	13 (21.3)	10 (16.4)	0.643

4.2.2. Vaccination of patients

In this study administering the first and second doses of both the BBIBP-CorV and BNT162b2 vaccines 21 days apart for all participants in both groups helps standardize the vaccination process. According to the NPH guideline the third dose of BNT162b2 mRNA COVID vaccine was administered at least four months (132–309 days) after the primary immunization.

Focusing on evaluating the total immunoglobulin (Ig) levels against the SARS-CoV-2 spike protein 1 receptor-binding domain (anti-SARS-CoV-2 S1-RBD) we compared them administering a third dose of the BNT162b2 vaccine in two different groups: the BBIBP-CorV vaccinated group following a heterologous regimen and the other group receiving three doses of BNT162b2 in a homologous regimen. The first sample was taken at the same time of administering of third vaccine, the second sample was collected after one month to evaluate the induced antibody level against SARS-CoV-2 S1-RBD. The study design is seen on Figure 1.

We performed a subgroup analysis based on age groups (≤ 60 years and >60 years) within the study cohort to find out how age influences the antibody responses to the vaccination regimen, specifically focusing on the correlation between antibody responses and time intervals after vaccination.

Patient questionnaires helped to analyze and review any possible infection and hospitalization due to COVID-19.




Figure 1. Study design of COVID vaccination (basic and third) in two groups and blood sampling

4.2.3. Laboratory methods

We used the Cobas® Anti-SARS-CoV-2 S serology test from Roche Diagnostics, (Mannheim, Germany) for measuring total Ig levels in serum samples to determine SARS-CoV-2 S1-RBD-specific antibody titres before and after the third dose of vaccination. The test measures antibody levels in blood samples and uses a cut-off value to determine seropositivity. In this case, the cut-off value used for seropositivity was ≥ 0.8 BAU/mL. A result above this threshold indicates the presence of detectable antibodies against the S1-RBD of the virus.

4.2.4. Statistical analysis

Normality Testing: The Kolmogorov–Smirnov test was employed to assess whether the data followed a normal distribution. This test is used to determine if a dataset significantly differs from a normal distribution.

Descriptive Statistics: Results were presented as mean \pm standard deviation (SD) for normally distributed data or as median with interquartile range (IQR) for non-normally distributed data. This provides a comprehensive view of the central tendency and spread of the data.

Comparison of two groups: The Wilcoxon test, a non-parametric test for comparing two independent groups, was used for analysing serology results. This test is suitable for non-normally distributed data and assesses if there is a significant difference between groups.

Chi-Squared Test: For comparing demographic parameters between the two groups, the chi-squared test was used. This statistical test assesses whether there is an association between categorical variables.

Correlation analysis: Spearman's correlation analysis was performed to examine relationships between variables. This non-parametric test assesses the strength and direction of monotonic relationships between variables.

Significance level: A significance level of $p < 0.05$ was chosen, indicating that results with a probability value below this threshold were considered statistically significant.

Software: The statistical analysis was conducted using the "R project" mathematical software via RStudio (Boston, MA, US).

5. Results

5.1. Study I.

5.1.1. Antibody response to PCV-13 vaccine

At baseline, pneumococcal antibody levels (IgG t = 0) in RA patients and in controls were 110.1 ± 68.2 mg/l and 124.0 ± 99.0 mg/l, respectively (Table 6.). Baseline levels in the RA and control groups did not show statistically significant difference. One month after vaccination, antibody levels (IgG t = 1) increased in both groups (RA: 247.7 ± 155.6 mg/l; controls: 417.7 ± 198.3 mg/l) compared to baseline ($p < 0.001$).

The mean increase in antibody levels between baseline and 4 weeks was 2.63-fold in the RA and 6.13-fold in the control group ($p = 0.016$). There was also a significant difference between the two groups. After two months, antibody levels (IgG t = 2) somewhat decreased in both groups, however, still remained significantly higher compared to baseline (RA: 207.6 ± 127.6 mg/l; control: 356.4 ± 171.2 mg/l, $p = 0.002$). The mean increase in antibody levels after 8 weeks were 2.08-fold and 5.2-fold in the RA and control groups, respectively, compared to baseline ($p = 0.039$) (Table 6., Figure 2.).

Table 6. Serum pneumococcal antibody level at baseline, after one and two months*

Study groups	Pneumococcal antibody levels mg/L			Rate of changes of IgG levels		
	IgG-0 baseline	IgG-1	IgG-2	0-1 month	0-2 months	p
RA (n=22)	110.10 ± 68.22	247.67 ± 155.23	207.57 ± 127.61	2.63±1.53-fold increase	2.08±0.87-fold increase	<0.001
Control (n=24)	124.02 ± 99.01	417.72 ± 198.33	356.35 ± 171.66	6.13±7.33-fold increase	5.20±5.32-fold increase	<0.001
p	0.585	0.002	0.002	0.016	0.039	

*IgG-0, baseline pneumococcal antibody level; IgG-1, pneumococcal antibody level after 1 month; IgG-2, pneumococcal antibody level after 2 months




Figure 2. Pneumococcal antibody levels at baseline (IgG 0), one month (IgG 1) and two months (IgG 2) after vaccination

5.1.2. Subgroup analysis: treatment with or without MTX

When comparing RA patients receiving ETA-MTX combination (n=15) and those receiving ETA monotherapy (n=7), the subgroup treated with combination produced a higher rate of increase in pneumococcal antibody levels after one month (2.89-fold increase) compared to the ETA monotherapy group (2.07-fold increase), however, the difference was not statistically significant ($p = 0.503$). After 2 months, the combination and monotherapy groups had 2.22-fold and 1.76-fold increases in antibody levels, respectively. The difference between the two subgroups was not significant ($p= 0.245$) (Table 7.).

Table 7. The effect of etanercept-methotrexate combination vs etanercept monotherapy on antibody response

Treatment	Pneumococcal antibody levels (mg/L)			Rate of changes of IgG levels	
	IgG-0 baseline	IgG-1	IgG-2	0-1 month	0-2 months
Combination (ETA+MTX) (n=15)	103.68±63.92	263.83±179.15	217.04±143.72	2.89±1.75-fold increase	2.22 ±0.94-fold increase
Monotherapy (ETA) (n=7)	123.87±80.19	213.04±86.08	187.27±89.96	2.07 ±0.73-fold increase	1.76 ±0.65-fold increase
p	0.531	0.488	0.622	0.503	0.245

5.1.3. Correlations between change of IgG and epidemiological data

Pneumococcal antibody levels (at 0, 1 and 2 months) were analyzed using various methods; results are shown in Table 8. There was no significant correlation between changes of IgG levels and DAS28, RF levels, anti-CCP levels and MTX dose.

Table 8. Spearman's correlations in RA group

	Change of IgG 0-1	Change of IgG 0-2
DAS28	R=-0.016 p=0.944	R=-0.079 p=0.728
Rheumatoid factor level	R=0.234 p=0.295	R=0.056 p=0.805
anti-CCP level	R=0.014 p=0.951	R=-0.114 p=0.621
MTX dose before vaccination	R=0.321 p=0.243	R=0.154 p=0.583
MTX dose after vaccination	R=0.388 p=0.190	R=0.135 p=0.660

IgG-0, baseline pneumococcal antibody level; IgG-1, pneumococcal antibody level after 1 month; IgG-2, pneumococcal antibody level after 2 months

Also indicated in Figure 3., the increase in antibody levels between baseline and week 8 negatively correlated with age (Spearman's $R = -0.431$; $p = 0.045$) in the RA group. Such significant correlation was not observed in the control group.




Figure 3. Correlation between age and rate of changes of pneumococcal antibody IgG levels (IgG 2/IgG 0) in RA patients

5.1.4. Vaccine safety and side effects

In the RA group, MTX treatment was stopped in two patients due to gastrointestinal side effects one month after vaccination, otherwise, their condition was stable, and they did not need any supplementary treatment (Table 9.). The average dose of MTX after vaccination increased in the RA group (12.33 ± 4.48 mg/week to 13.08 ± 4.23 mg/week), but this change was not significant ($p=0.337$). During the treatment follow-up period after vaccination, the mean value of DAS28 did not increase over 3.2. Thus, PCV-13 vaccination did not increase disease activity in the group of RA patients.

During the post-vaccination follow-up period, patients had no complaints, such as fever, pain or infections. In summary, there were neither clinically significant side effect nor local or systemic reactions were observed in any of the patients during the 2-month follow-up period.

Table 9. Treatment follow-up after vaccination in study group

RA patients	Before vaccination	After vaccination	p value
Etanercept monotherapy (n)	7	9	0.755
Etanercept + MTX (n)	15	13	
Dose of MTX (mg/week)	12.33±4.48	13.08±4.23	0.337
Without corticosteroid treatment (n)	17	17	1.000
Combined with corticosteroids (n)	5	5	
Dose of corticosteroid (mg/day)	2.8±1.10	3.2±1.10	0.374
DAS28	2.79±0.62	2.93±0.79	0.349

Table 10/a. and Table 10/b. show the subgroup of 5 RA patients treated with corticosteroids. Considering the very small number of this subgroup, statistical analysis was not performed. The corticosteroid dose was stable in 4 patients, only one patient (No 3) needed higher dose of corticosteroids after vaccination (increased from 2 mg to 4 mg). Comparing patients treated with corticosteroids (5 patients) and those without corticosteroids (17 patients), DAS28 value did not change significantly before (2.94 ± 0.93 and 2.78 ± 0.62 ; $p=0.564$) and after (2.79 ± 0.45 and 2.97 ± 0.87 ; $p=0.673$) vaccination. None of the RA patients needed the introduction of corticosteroids after vaccination. In the control OA group, there were no changes in medications within 2 months after PCV13 administration.

Table 10/a. Follow-up of subgroup of RA patients on corticosteroid treatments 1.

Patient No	Gender (age-year)	DAS28 before vaccine	DAS28 after vaccine	Corticosteroid dose before vaccine (mg/day)	Corticosteroid dose after vaccine (mg/day)	MTX dose before vaccine (mg/week)	MTX dose after vaccine (mg/week)
1	Female, 43	3.1	3.34	4	4	15	15
2	Female, 56	2.95	3.0	4	4	20	20
3	Female, 60	3.68	2.1	2	4	5	0
4	Male, 47	1.54	2.76	2	2	15	15
5	Male, 53	3.42	2.76	2	2	0	0

Table 10/b. Follow-up of subgroup of RA patients on corticosteroid treatments 2.

	Patients on corticosteroids (n=5)	Patients without corticosteroids (n=17)	p value
DAS28 before vaccine	2.94±0.93	2.78±0.62	0.564
DAS28 after vaccine	2.79±0.45	2.97±0.87	0.673

5.1.5. Predictive factors and antibody response in RA patients

We aimed to determine prognostic factors, which predict antibody response. We performed univariate logistic regression analysis and investigated how different parameters affected the inadequate antibody responses in one and two months after vaccination in the RA group (Table 11.). There were no correlations between gender, age, treatment strategy (ETA with or without MTX, with or without corticosteroids), immunolaboratory tests (RF levels, anti-CCP levels), disease activity (DAS28-CRP) and inadequate antibody responses.

Table 11. Univariate logistic regression estimates of the effects of various factors on odds of inadequate immune response in RA group (after 1 and 2 months of vaccination)

Epidemiological data	1 month after vaccination			2 months after vaccination		
	Odds Ratio (OR)	95% CI	p	Odds Ratio (OR)	95% CI	p
Gender, age						
Male vs. female	0.281	0.026-3.067	0.298	0.136	0.012-1.513	0.105
Age ≥ 60 ys. vs < 60 ys	1.281	0.228-7.187	0.779	2.333	0.400-13.609	0.346
Treatment						
ETA+MTX vs ETA monotherapy	0.889	0.144-5.479	0.998	0.857	0.141-5.228	0.867
With vs without corticosteroids	0.286	0.026-3.196	0.309	1.313	0.168-10.264	0.767
Immunolaboratory tests						
RF level positive vs. negative	0.636	0.072-5.613	0.684	1.250	0.143-10.940	0.840
Anti-CCP level positive vs. negative	0.625	0.105-3.707	0.605	0.700	0.116-4.232	0.093
Disease activity						
DAS28 >3.2 vs ≤ 3.2	2.75	0.355-21.30	0.333	4.500	0.413-49.077	0.217

5.1.6. Practical recommendations of pneumococcal vaccination in RA patients

As listed in our specific aims, reviewing the literature; primarily international recommendations, and performing our PCV-13 study, we aimed to compile some practical recommendations that could be used in everyday practice.

Firstly, conjugated pneumococcal vaccination (PCV-10, PCV-13) is recommended from 2 months of age. This has been accepted in most of European Union (EU) countries and in the United States, however, only 6 EU countries (Bulgaria, France, Hungary, Latvia, Poland, Slovakia) included it in their mandatory childhood vaccination protocol [77].

The country-specific adulthood pneumococcal vaccination guidelines are even more problematic in the EU. Ten countries have absolutely no guidelines. In another 10 countries, only PPVs are recommended. In 6 countries, only PCVs are recommended. There are only 5 countries (Finland, Greece, Hungary, Italy, Luxemburg) where international, sequential pneumococcal vaccination protocol has been introduced. In addition, there is no specific clinical guideline for pneumococcal vaccination of patients with AIRD.

There are five reviewed sets of pneumococcal vaccination available worldwide for immunocompromised patients [77-81]. Based on the EULAR [77], WHO [79], ACIP [78], IDSA [80] and Canadian Dermatology Association [81] reviews and recommendations and our results, the most relevant cornerstones of these recommendations are summarized in Table 12.

Table 12. Checklist for optimal decision making in management of pneumococcal vaccination in RA patients

Disease activity ⁷⁷	Low DAS28 \leq 3.2	Vaccinate
	High DAS28 $>$ 3.2	Do not vaccinate
Biologic therapy ^{77,78}	anti-TNF- α , abatacept, tocilizumab	Vaccinate
	rituximab	Vaccinate \geq 5 months after the last dose of rituximab and at least 4 weeks before the next dose of rituximab
Other therapy ⁷⁷	Concomitant DMARDs and corticosteroid doses	Vaccination based on the ACIP recommendation of low levels of immunosuppression*
Sequential administrations of PCV-13 + PPV-23 ^{77,78}	Clear assessment of vaccination history is needed The vaccination scheme is different if the patient has previous PPV-23 (follow <i>Table 3</i>)	

* low-level of immunosuppression: $<$ 0.4 mg/kg weekly use of MTX; $<$ 3.0 mg/kg daily use of azathioprine; $<$ 1.5 mg/kg daily use of 6-mercaptopurine; $<$ 20 mg daily use of corticosteroids, for more than 14 days [77]

For the optimal decision making about pneumococcal vaccination, there are three issues that must be assessed by a multidisciplinary team (rheumatologist, experienced infectious disease specialist in vaccinology, general practitioner): 1. disease activity, 2. ongoing immunosuppressive therapy, 3. vaccination history. To prevent flare of autoimmune diseases, pneumococcal vaccines must be administered in the state of low disease activity ($\text{DAS28} \leq 3.2$). The optimal timing of administration of vaccines would be 2 weeks before initiation of DMARDs therapy in low disease activity. During anti-TNF- α , abatacept or tocilizumab therapy, the immunisation can be started. Patients treated with rituximab; due to B-cell depletion, must be vaccinated more than 5 months after the last rituximab dose, and at least 4 weeks before the next dose [77, 81]. Review of the immunisation history is important to decide how sequential pneumococcal vaccination should be conducted. Immunologically, the best option in vaccine-naïve AIRD patient is to start with PCV-13 first, followed by PPV-23 administration after 2 months [77, 81].

5.2. Study II.

5.2.1. Antibody response in heterologous and homologous vaccination groups

The baseline comparison of anti-SARS-CoV-2 S1-RBD antibody levels between the BBIBP-CorV and BNT162b2 groups (20.8 [6.6–98.7] BAU/mL vs 903,4 [528.8–1811.7] BAU/mL, respectively) (Figure 4.) yielded a statistically significant ($p < 0.0001$) difference. It's notable that both the BBIBP-CorV cohort and the BNT162b2 group showed a significant increase in antibody levels after receiving the third dose of vaccine. The anti-SARS-CoV-2 S1-RBD antibody levels substantially rose in both groups compared to their respective baseline levels ($p < 0.0001$). The BBIBP-CorV cohort exhibited a median antibody level of 27,195 [15,604–42,754] BAU/mL after the third dose, while the BNT162b2 group displayed a median level of 24,492 [13,779–42,671] BAU/mL.

The comparison of the increase in antibody titers (after/before total antibodies) between the heterologous (BBIBP-CorV) and homologous (BNT162b2) vaccination cohorts revealed a significant difference (Figure 5.). Specifically, the ratio of antibody levels after the third vaccination to baseline levels was notably higher in the heterologous vaccination group compared to the homologous group ($p < 0.0001$). This finding suggests that the increase in antibody levels following the third-dose vaccination was more pronounced in the heterologous vaccination group (BBIBP-CorV) compared to the homologous group (BNT162b2). The higher ratio of post-third dose to baseline antibody levels in the

heterologous cohort indicates a potentially stronger immune response elicited by the mix-and-match (BBIBP-CorV + BNT162b2, heterologous) vaccination approach.




Figure 4. Anti-SARS-CoV-2 total Ig levels before and after third dose of BNT162b2 vaccination in BBIBP-CorV and BNT162b2 groups




Figure 5. Ratio of total Ig levels (after/before of third dose of BNT162b2 vaccine) between BBIBP-CorV and BNT162b2 groups

5.2.2. Age-related subgroup analysis of SARS-CoV-2 total Ig levels

Investigating potential differences in the humoral immune response induced by the third-dose vaccination based on age groups (under or over 60 years) is an insightful approach. That's an interesting and somewhat unexpected finding that age didn't appear to influence the anti-SARS-CoV-2 total Ig levels in either the pre-third dose or post-third dose stages within these cohorts (Figure 6.):

1. Pre-third dose Ig levels: The absence of a difference in pre-third dose Ig levels between older (>60 years) and younger participants in either study group suggests that, before the third-dose vaccination, age did not seem to impact the baseline antibody levels against SARS-CoV-2 S1-RBD within these cohorts.
2. Similarly, the finding that post-third dose total Ig levels didn't elevate to a greater extent in younger subjects, especially in the homologous vaccination group, implies that the third-dose vaccine might not have resulted in significantly higher antibody responses in younger individuals compared to older ones within the studied cohorts.

The subgroup analysis confirmed further that only the type of vaccine significantly influenced the baseline anti-SARS-CoV-2 total Ig levels aligns.




Figure 6. Age-related effect on anti-SARS-CoV-2 S1-RBD total Ig titers within 2 cohorts before and after the third-dose vaccination

5.2.3. Time-related analysis of SARS-CoV-2 total Ig levels after the third-dose vaccination

The observed moderate but significant correlation between anti-SARS-CoV-2 total Ig levels after the third-dose vaccination and the time interval between the second and third doses in both groups is an important finding. A Spearman's correlation coefficient of 0.22 ($p = 0.015$) suggests a positive relationship between these variables. This correlation indicates that the efficacy of the third-dose vaccine, as measured by the increase in antibody levels, was most pronounced when the time interval between the basic (initial) and third-dose vaccinations ranged from around 6 to 8 months (Figure 7.). In the BBIBP-CorV group, the peak of antibody levels following the third-dose vaccination occurred approximately 8 months later than in the BNT162b2 group. Within this time frame, the third-dose vaccination seemed to induce a more substantial increase in antibody levels.




Figure 7. Correlation of Timing of second and third dose of vaccine and antibody responses

5.2.4. Vaccine safety and side effects

The administration of three vaccine doses to all subjects was both safe and well-tolerated in our study. Additionally, the incidence of COVID-19 infection during the basic immunization regimen was notably low, with only one patient (1.7%) acquiring a mild case of the infection in the BBIBP-CorV group, occurring shortly after the second vaccine dose. Importantly, this individual did not require hospitalization, indicating a mild and manageable case.

Notably, no cases of COVID-19 developed in the BNT162b2 group or in any participants from either group after the administration of the third-dose vaccine. The absence of serious or clinically significant side effects further supports the safety profile of the vaccination regimen used in your study.

6. Discussion

6.1. Study I.

6.1.1. Studies of PPV-23 in RA patients treated with biologics

Previously, in the PPV era, there were more studies in which similar or mild immune responses were detected in biologics-treated versus non-treated patients. Between 2004-2012, ETA and infliximab were the first studied anti-TNF- α agents in relation with pneumococcal vaccination [82-85]. The mean antibody response to PPV-23 vaccination was not impaired in patients on ETA or infliximab in most studies. In 2007, Kaine et al [86] investigated PPV-23 vaccination in adalimumab-treated RA patients. They concluded that adalimumab had no negative effect on PPV-23 vaccination, and that patients responded well to the vaccine [86].

Since 2014, the efficacy of PPV-23 vaccine administered to biologic-treated RA patients has been investigated. These studies using certolizumab pegol and golimumab confirmed a protective immune response to the PPV-23 vaccine in these patients [87, 88]. Other biologics, such as tocilizumab [89, 90] and abatacept [91, 92], did not impair antibody responses to PPV-23 in RA patients.

Two studies included rituximab-treated RA patients. These studies suggested that the B-cell inhibitor rituximab impaired immune responses to PPV-23 [93, 94]. Izumi et al [95] published a prospective, multicentre, double-blind, randomized, placebo-controlled trial of PPV-23 vaccination in RA patients. Altogether, 900 RA patients were randomized to two groups (464 PPV-23-vaccinated and 436 non-vaccinated). The vaccinated group included 257, while the non-vaccinated group included 253 biologic-treated RA patients. The incidence of pneumococcal pneumonia was one of the primary endpoints of the study. The results showed no effectivity of PPV-23 vaccination in RA patients treated with any DMARDs or corticosteroids, regardless of dose. Moreover, there was no significant difference in the incidence rate of pneumonia caused by pneumococcus between vaccinated and non-vaccinated groups [95].

6.1.2. Studies of PCV in RA patients treated with biologics

There have been limited data available about the immunogenicity of the 13-valent PCV-13 administered in immunocompromised conditions. In recent literature, only one completed study investigated the immunogenicity of PCV-13 in patients suffering from immunocompromised condition [46]. The vaccine showed good effectivity in chronic lymphocytic leukaemia patients [46].

Kapetanovic et al [96] compared the heptavalent conjugated pneumococcal vaccine (PCV-7); approved for children only, in adult RA patients receiving ETA, rituximab and adalimumab with PPV-23. There were no differences in antibody responses for PCV-7 or PPV-23. Both vaccines induced a protective response during anti-TNF- α treatment in RA patients [96].

PCV-7 was also investigated in RA patients with concomitant rituximab, abatacept and tocilizumab treatment [50]. The result of the study concluded that rituximab and abatacept; but not tocilizumab, might impair antibody responses to PCV-7 [50].

Based on the poor clinical data on the immunogenicity of PCV-13 in immunocompromised AIRD patients, here we evaluated the immunogenicity and safety of the new PCV-13 vaccine in RA patients undergoing ETA therapy. Our results showed a clinically significant (> 2 -fold) elevations of antibody levels, as a protective level was observed after one- and two-months post-vaccination, compared to baseline in both RA and control groups. Pneumococcal antibody levels significantly increased four weeks after vaccination in both groups, then it somewhat decreased by week 8 in both groups, however, these levels remained significantly higher compared to baseline antibody levels. Our investigation was the first to show protective pneumococcal antibody levels after using the PCV-13 vaccine in RA patients treated with ETA.

Since January 2024, two new conjugate vaccines with broader serotype coverage have been introduced in Hungary [97]. The 15-valent vaccine, PCV-15 (Vaxneuvance®), was approved in the EU on December 13, 2021, and has been available in Hungary since January 2024 for individuals aged six weeks and older [98]. In 2024, this vaccine replaced PCV-13, which had previously been part of the mandatory childhood immunization schedule in Hungary [99]. The other vaccine, PCV-20 (Apexxnar®/Prevenar 20), containing 20 serotypes, was approved in the EU on February 14, 2022, and also became available in Hungary in January 2024 for administration from six weeks of age [100].

According to Hungary's current vaccination guidelines the choice and sequence of vaccination for adults depend on the individual's prior immunization history and the serotype count of the vaccine to be administered. Sequential immunization remains recommended with the 23-valent polysaccharide vaccine (PPSV23), with some adjustments incorporating the newer, higher-valency PCV-15 and PCV-20 vaccines. Of the two main international guidelines currently in place (EULAR-2019 and ACR-2022), only the updated American guidelines address the use of these newer pneumococcal vaccines for patients with AIRD [101, 102]. EULAR is set to review its guidelines in October 2024.

For further insights into the effectiveness of these vaccines in adults with impaired immunity, future studies will provide necessary data, as current literature is still lacking on this topic.

6.1.3. Concomitant immunosuppressive treatment affecting antibody response: MTX

Several studies and meta-analyses investigated antibody response for PPV-23 during biologic therapy with concomitant MTX treatment in RA patients. Most of them demonstrated a decreased antibody response for PPV-23 in patients treated with biologics and MTX [83-85, 103, 104].

Studies investigating PCV-7 in RA patients treated with combined biologic + MTX therapy showed similar results. Immunological responses to PCV-7 were reduced with concomitant MTX treatment [104, 105]. Kapetanovic et al [106] performed a comparative study in which they analysed the immune response to PCV-13 in RA patients treated with or without MTX. This group demonstrated a decreased immune response to PCV-13 during MTX therapy [106].

In our present study, we investigated whether ETA+MTX combination therapy had any effect on antibody response to PCV-13 compared to ETA monotherapy in RA patients. Surprisingly, after 1 and 2 months, patients in the subgroup with MTX combined therapy had better responses than those receiving ETA monotherapy, but the differences were not significant. This observation investigated by univariate analysis showed that patients on biologics with concomitant MTX therapy had similar antibody response compared to those not treated with MTX combination.

MTX promotes cell apoptosis [107]. Apoptosis affects the highly activated T-cells in a dose- and time-dependent manner [107]. Van Aalst et al [108] reviewed the effect of MTX and biologics (anti-TNF- α , rituximab) in RA patients during pneumococcal vaccination (PPV-23, PCV-7 or PCV-13). Decreased initial antibody responses were observed in all vaccines compared to controls during the administration of all immunosuppressive drugs. However, patients treated with anti-TNF- α had stronger immune responses than those treated with other immunosuppressive agents [108].

6.1.4. Concomitant immunosuppressive treatment affecting antibody response: corticosteroids

Visvanathan et al [84] investigated PPV-23 vaccinated RA patients on infliximab in two groups treated with or without oral corticosteroids. The surprising result confirmed that added the corticosteroid elicited superior antibody response after PPV-23 vaccination [84].

Kapetanovic et al [47] confirmed better immune responses to PCV-7 in RA patients treated with anti-TNF- α combined with concomitant corticosteroid therapy (mean doses of 8.8-14 mg/week). Nagel et al [48] analysed if there was any correlation between antibody levels and increasing of subsequent events of serious pneumococcal infections after vaccination in 248 PCV-7 vaccinated RA patients. Higher dose of corticosteroid (≥ 7.5 mg/day) was found to be a significant predictor of serious infections. In this trial, neither biologics nor MTX monotherapy nor combination treatment were predictive factors for serious pneumococcal infections [48].

In our study, we did not analyse statistically corticosteroid-treated patients separately, due to the small number of this subgroup. In our univariate regression analysis, added corticosteroid therapy did not predict an impaired antibody response. Thus, our PCV-13 vaccinated RA patients had a good immune response. The immune response had not been impaired by MTX combination. Protective immune response was seen 2 months after vaccine administration.

6.1.5. Older age as a predictive factor for antibody response

Two studies using PCV-7 vaccine in RA patients concluded that older age was an independent predictor of inadequate antibody response [47, 48]. As we observed, significant negative correlation was found between the increasing antibody level (IgG2/IgG0) and age,

2 months after vaccination in the RA group. These results suggest that early initiation of pneumococcal vaccination in younger age produces a more robust adequate antibody response in RA patients.

6.1.6. Limitations of the study

There are some limitations of our study. RA patients treated with MTX monotherapy or without immunosuppressive drugs were not enrolled in the study, because the number of these patients at our department is limited. The control group included OA patients. Possibly another control group of RA patients would have been useful (e.g. drug-naive new RA patients), but infeasible for this purpose. We did not want to include patient population treated with different biologics.

The number of patients within the RA group; especially in the combination versus monotherapy subgroups, were relatively low. However, it was not easy to do an at least two months' prospective vaccination study using ETA monotherapy only.

In this study, we only assessed total antibody level; any specific IgGs against pneumococcal polysaccharide serotypes were not measured.

Moreover, the 2-month post-vaccination follow-up period was not enough to determine long term antibody response. The duration of protection after PCV-13 vaccination is still unknown, but it probably lasts at least several years. Long-term follow-up in order to assess the clinical occurrence of pneumococcal infections was not performed.

6.2. Study II.

6.2.1. The effect of third-dose BNT62b2 vaccination on the heterologous (BBIBP-CorV) and homologous (BNT162b2) groups

The scarcity of heterologous vaccination studies—specifically those involving the use of BNT162b2 after two initial BBIBP-CorV vaccinations—in non-Caucasian populations highlights an important gap in our understanding of vaccine interactions and effectiveness across diverse demographic groups [60-63].

Kanokudom et al [109] applied a protein subunit vaccine following a two-dose basic vaccination regimen involving BBIBP-CorV, seems to explore the potential of a heterologous vaccination strategy. Using a different type of vaccine, such as a protein subunit

vaccine, after completing the initial BBIBP-CorV regimen, aims to assess the immune response generated in this sequence [109].

The study conducted by Hueda-Zavaleta et al [110] in Peru, which involved a temporal separation of 7 months between BBIBP-CorV and BNT162b2 vaccinations for healthcare workers, appears to focus on the effects of a heterologous vaccination schedule on humoral immunity. The findings indicating a more pronounced increase in humoral immunity among individuals without prior SARS-CoV-2 infection after receiving the heterologous BNT162b2 regimen are noteworthy. This suggests that the sequential use of different vaccines, especially with a considerable time gap, might induce a more robust immune response in individuals who haven't had prior exposure to the virus [110].

The study conducted by Vargas-Herrera et al [63] in Peru showed a significant increase in geometric mean IgG levels following the administration of the third-dose BNT162b2 after prior BBIBP-CorV vaccination. This finding suggests that using a different vaccine as a third dose, specifically BNT162b2 after BBIBP-CorV, resulted in a notable enhancement of IgG antibody levels [63].

The study conducted by Moghnieh et al [60] in Lebanon mirrors findings from other research, highlighting the significance of heterologous regimen. This group observed that a heterologous third-dose vaccination—using a different vaccine than the initial one—was significantly associated with higher anti-spike IgG geometric mean titers compared to the levels observed after receiving a homologous third-dose BNT162b2 vaccine [60].

The research conducted by Park et al [62] involving Korean health professionals revealed that administering a third-dose BNT162b2 after the second dose of BBIBP-CorV provided more effective protection against laboratory-confirmed COVID-19. This comparative analysis indicated that the heterologous approach of using a different vaccine (BNT162b2) as a third-dose after the initial BBIBP-CorV doses offered greater protection against COVID-19 compared to not receiving a third-dose vaccine or receiving a third-dose BBIBP-CorV [62]. The safety and tolerability of heterologous vaccination, particularly using BNT162b2 after BBIBP-CorV were confirmed, as indicated by multiple studies [60, 62, 63, 109, 110].

Our real-world study provided valuable insights into the immunogenicity and efficacy of the third-dose BNT162b2 vaccination in individuals who had previously received either two BBIBP-CorV vaccinations (heterologous regimen) or two BNT162b2 vaccinations (homologous regimen). Both vaccination regimens resulted in high anti-SARS-CoV-2 Ig levels after the third-dose vaccine compared to baseline.

The 2x BBIBP-CorV + BNT162b2 combination provided adequate catch-up immunization for individuals who did not have access to the 2x BNT162b2 primary vaccination, emphasizing the societal value of heterologous vaccination.

However, the heterologous regimen (BBIBP-CorV followed by BNT162b2) showed a significantly higher increase in antibody levels (after/before total Ig levels ratio) compared to the homologous regimen. Age did not influence anti-SARS-CoV-2 Ig levels in either regimen. There were no significant differences in antibody levels before or after the third-dose vaccination between individuals older than 60 years and younger participants in both groups. The efficacy of the third-dose vaccine was most pronounced around 6–8 months after the initial vaccination schedule.

A correlation was observed between the timing of the third-dose vaccination and anti-SARS-CoV-2 Ig levels, suggesting that the most effective reinforcement occurred within this time frame. Importantly, the study highlighted that the third dose of BNT162b2 effectively enhanced the effects of the two-dose BBIBP-CorV vaccination. This finding supports the potential for cross-regimen vaccination strategies to strengthen immune responses. A debated question regarding COVID vaccinations was whether the third dose should be considered part of the primary vaccination strategy or viewed as a booster shot. During the pandemic, it became particularly clear in the case of immunosuppressed patient groups that their primary immunization strategy includes three doses, meaning an extended vaccination series, which was also highlighted in the Centers for Disease Control and Prevention's COVID vaccination recommendations. In our study, when compared to several primary immunization recommendations for non-replicating vaccines — where three doses are recommended — the third dose given within a six-month timeframe clearly improved the immune response. We did not specifically study the immunosuppressed population in our paper.

6.2.2. Strengths and limitations of the study

The strengths of our study:

1. Pioneering exploration: Being one of the initial studies exploring the use of a BNT162b2 heterologous regimen in individuals who previously received two BBIBP-CorV vaccinations in a Caucasian population is a notable strength. This contributes to filling the gap in knowledge regarding mixed vaccine schedules in specific demographic groups.

2. Comparative analysis: Comparing the heterologous regimen directly with a homologous protocol (three shots of BNT162b2) provides valuable insights into the comparative efficacy and potentially informs vaccination strategies.

3. Age-group analysis: Evaluating the efficacy and safety of the vaccination regimen across various age groups is crucial. This consideration helps understand potential variations in response based on age, which is essential for tailoring vaccination recommendations.

There are some limitations of our study:

1. Single-Centre Nature: The single-centre aspect might limit the generalizability of the findings. Multi-centre studies can offer more diverse data, reflecting broader populations and healthcare settings.

2. Biomarker measurement: Measuring only the level of anti-SARS-CoV S1-RBD antibodies for the evaluation of humoral immunity might provide an incomplete picture of the immune response, since the applied antibody test is surrogate to the gold standard plaque reduction neutralization test.

7. Summary

7.1. Study I.

Rheumatoid arthritis patients are at risk of pneumonia due to the nature of their disease condition and immunosuppressive therapy. Pneumococcal vaccination can prevent serious pneumococcal infections. Our study confirmed:

1. Effectiveness of conjugated pneumococcal vaccination: the PCV-13 was effective 2 months after immunization in RA patients treated with etanercept.

2. Etanercept combination with MTX therapy had better immune response to vaccine than those with etanercept monotherapy.

3. Safety and tolerability: The vaccination was safe, did not affect autoimmune disease activity, and the condition of RA patients was stable during, and after immunisation in the follow-up period.

4. Age-dependent response: Vaccination with PCV-13 in younger age produces a more robust AIR in RA patients.

In summary, the most common pneumococcal pneumonia can be prevented in RA patients treated with etanercept and concomitant MTX therapy. The international data about

immune response to pneumococcal vaccination during biologics and concomitant MTX or corticosteroids is contradictory. Understanding of immune responses to pneumococcal vaccination in AIRD patients treated with immunosuppressive drugs requires more comparative trials. Effective reduction of pneumococcal vaccine-preventable infections improves quality of life of RA patients. Special issues of immunisation in AIRD have to be assessed in a regular updated country- specific recommendations reviewed by experts.

7.2. Study II.

Our study's conclusions provide critical insights into the efficacy of third dose COVID vaccinations, specifically with BNT162b2 following a BBIBP-CorV vaccination regimen. The list of the key findings is:

1. Comparison of Immunization Regimens: we confirmed that two doses of BNT162b2 induce higher anti-SARS-CoV-2 RBD total Ig antibody levels compared to two doses of BBIBP-CorV which establishes a disparity in the immune response generated by these vaccines.
2. Effectiveness of Heterologous Regimen: Demonstrating that a third dose of BNT162b2, administered after two doses of BBIBP-CorV, effectively reinforces anti-SARS-CoV-2 RBD humoral immune responses more than a homologous regimen of three BNT162b2 doses is a crucial finding. This highlights the potential effectiveness of a third vaccine dose in a heterologous regimen for enhancing immune responses.
3. Age-independent response: Highlighting that the humoral immune responses observed were not significantly influenced by age but correlated with the timing of vaccine administration underscores the importance of the vaccination schedule in impacting immune response.
4. Safety and tolerability: Affirming the safety and tolerability of the third-dose vaccination is essential information for healthcare decision-making and public confidence in vaccination strategies.
5. Future Research Directions: Emphasizing the need for further studies with larger participant numbers is critical for more robust and generalizable findings. Specifically, advocating for additional research involving Caucasian individuals receiving BBIBP-CorV vaccinations acknowledges the importance of diversity in vaccine research.

These findings have significant implications for vaccination policies and clinical decisions, emphasizing the importance of ongoing research for optimizing vaccination protocols.

8. Összefoglalás (Summary in Hungarian)

8.1. Tanulmány I.

A rheumatoid arthritis az autoimmun alapbetegség és az összetett immunszuppresszív terápia miatt a pneumonia fokozott kockázatával jár. A pneumococcus elleni vakcináció megelőzheti a súlyos pneumococcus fertőzéseket.

Kutatásunk igazolta, hogy a jelenleg javasolt PCV-13 hatékony volt etanercepttel kezelt RA betegekben az oltás után két hónappal. MTX-al kombinált kezelés mellett erősebb immunválasz volt kiváltható, mint az etanercept monoterápia mellett. Az oltás biztonságosnak bizonyult, nem volt hatással az autoimmun betegség aktivitására, és az RA-s betegek állapota mindvégig stabil maradt az immunizációt követő periódusban. Fiatalabb korban kezdeményezett PCV-13 oltás erőteljesebb AIR-t eredményezett RA beteginkben.

Összegezve, a gyakori pneumococcus pneumonia megelőzhető az etanercept és MTX kombináció mellett RA betegekben. A nemzetközi adatok ellentmondásosak a biológiai terápiával kombinált MTX és szteroid terápiát illetően. Ahhoz, hogy megértsük a pneumococcus oltásra adott immunválaszt immunszuppresszív terápiával kezelt AIRD-ben szenvedő betegeknél, több összehasonlító tanulmányra van szükség. A pneumococcus vakcinával megelőzhető fertőzések hatékony csökkentése javítja az RA betegek életminőségét.

Az autoimmun reumatológiai betegségekben szenvedők speciális immunizációjára vonatkozó, ország-specifikus és naprakész ajánlások elkészítése mindenképpen tanácsos szakértői munkacsoport segítségével.

8.2. Tanulmány II.

Tanulmányunk kritikus betekintést nyújtott a harmadik COVID oltás hatékonysági eredményeibe kifejezetten a harmadikként BNT162b2-vel oltott BBIBP-CorV oltási sémába. A legfontosabb eredmények a következők:

1. Immunizációs sémák összehasonlítása: igazoltuk, hogy a két alapoltási sorból álló BNT162b2 magasabb anti-SARS-CoV-2 RBD Ig antitest szintet indukál, mint a két alapdózisból álló BIBP-CorV, ami a vakcinák által generált immunválasz eltérését mutatja.

2. A heterológ oltási séma hatékonysága: Kulcsfontosságú eredmény, hogy a BNT162b2 harmadik dózisa két alapdózis BBIBP-CorV után hatékonyabban erősíti a SARS-CoV-2 RBD elleni humoralis immunválaszt, mint a homológ sémában adott 3 BNT162b2. Mindez a heterológ csoportban adott harmadik oltás potenciális hatékonyságára utal.

3.Életkor-független válasz: Annak kiemelése, hogy az immunválaszokat nem befolyásolta szignifikánsan az életkor, de korreláltak a vakcina beadásának időzítésével, az oltási ütemterv fontosságát hangsúlyozza az immunválasz befolyásolásában.

4. Biztonság és tolerálhatóság: A harmadik oltás biztonságossága és tolerálhatósága alapvető információ az egészségügyi döntéshozatalhoz és az oltási stratégiákba vetett általános bizalomhoz.

5. Jövőbeli kutatási irányok: Nagyobb esetszámmal végzett további tanulmányok szükségességének hangsúlyozása kritikus fontosságú a robosztusabb és általánosíthatóbb eredmények érdekében. A BBIBP-CorV oltásban részesülő kaukázusi egyének bevonásával végzett további kutatások támogatása biztosítja a változatosság fontosságát a vakcina kutatásban.

A fenti eredmények jelentős hatással vannak az oltási ajánlásokra és a klinikai döntéshozatalokra hangsúlyozva a folyamatos kutatások fontosságát az oltási protokollok optimalizálása érdekében.

9. References

9.1. References of dissertation

1. http://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en.
2. Ewig S, Torres A: **Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality.** *Eur Respir J* 2011, **38**(2):253-260.
3. Welte T, Torres A, Nathwani D: **Clinical and economic burden of community-acquired pneumonia among adults in Europe.** *Thorax* 2012, **67**(1):71-79.
4. McCullers JA: **Insights into the interaction between influenza virus and pneumococcus.** *Clin Microbiol Rev* 2006, **19**(3):571-582.
5. Torres A, Peetermans WE, Viegi G, Blasi F: **Risk factors for community-acquired pneumonia in adults in Europe: a literature review.** *Thorax* 2013, **68**(11):1057-1065.
6. Lu H, Stratton CW, Tang YW: **Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.** *J Med Virol* 2020, **92**(4):401-402.
7. Zheng J: **SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat.** *Int J Biol Sci* 2020, **16**(10):1678-1685.
8. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY *et al*: **A new coronavirus associated with human respiratory disease in China.** *Nature* 2020, **579**(7798):265-269.
9. **COVID-19 Coronavirus Pandemic Weekly Trends.** <https://www.worldometers.info/coronavirus> 2022.
10. Teh CL, Wan SA, Ling GR: **Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality.** *Clin Rheumatol* 2018, **37**(8):2081-2086.
11. Goldblatt F, Chambers S, Rahman A, Isenberg DA: **Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality.** *Lupus* 2009, **18**(8):682-689.
12. Falagas ME, Manta KG, Betsi GI, Pappas G: **Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.** *Clin Rheumatol* 2007, **26**(5):663-670.
13. Wotton CJ, Goldacre MJ: **Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses.** *J Epidemiol Community Health* 2012, **66**(12):1177-1181.
14. Franklin J, Lunt M, Bunn D, Symmons D, Silman A: **Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis.** *Ann Rheum Dis* 2007, **66**(3):308-312.
15. Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J: **Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study.** *J Rheumatol* 1998, **25**(10):1900-1907.
16. Smolen JS, Aletaha D, McInnes IB: **Rheumatoid arthritis.** *Lancet* 2016, **388**(10055):2023-2038.
17. Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE *et al*: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.** *Ann Rheum Dis* 2023, **82**(1):3-18.
18. Damjanov N, Nurmohamed MT, Szekanecz Z: **Biologics, cardiovascular effects and cancer.** *BMC Med* 2014, **12**:48.

19. Poór G: **Biológiai terápia a hazai reumatológiában.** *Medicina, Budapest.* 2017:137-142.
20. Hodinka L, Bálint P, Bender T, Czirják L, Géher P, Héjj G, Hittner Gy, Kiss E, Kovács L, Nagy Gy, Ortutay J, Poór Gy, Tamási L, Szekanecz Z. : **Az arthritisek kezelése szintetikus és biológiai betegségmódosító gyógyszerekkel.** . *Immunol Szemle* 2015, **7**(1):4-25.
21. Szekanecz Z, Szanto S, Szabo Z, Vancsa A, Szamosi S, Bodnar N, Szucs G: **Biologics - beyond the joints.** *Autoimmun Rev* 2010, **9**(12):820-824.
22. Tamási L, Szekanecz Z: **A biológiai terápia lehetőségei az arthritisek és a szisztémás autoimmun kórképek kezelésében.** *Orv Hetil* 2007, **148** (13 Suppl 1):63-70.
23. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C: **Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.** *Ann Rheum Dis* 2013, **72**(2):165-178.
24. Wolbink GJ, Aarden LA, Dijkmans BA: **Dealing with immunogenicity of biologics: assessment and clinical relevance.** *Curr Opin Rheumatol* 2009, **21**(3):211-215.
25. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B: **Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.** *Arthritis Rheum* 2006, **54**(3):711-715.
26. Tigoi CC, Gatakaa H, Karani A, Mugo D, Kungu S, Wanjiru E, Jomo J, Musyimi R, Ojal J, Glass NE *et al*: **Rates of acquisition of pneumococcal colonization and transmission probabilities, by serotype, among newborn infants in Kilifi District, Kenya.** *Clin Infect Dis* 2012, **55**(2):180-188.
27. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R, Soininen A, Edmunds J *et al*: **Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study.** *J Infect Dis* 2005, **192**(3):387-393.
28. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, Pneumococcal Carriage G: **The fundamental link between pneumococcal carriage and disease.** *Expert Rev Vaccines* 2012, **11**(7):841-855.
29. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T *et al*: **Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.** *Lancet* 2009, **374**(9693):893-902.
30. Hausdorff WP, Bryant J, Paradiso PR, Siber GR: **Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.** *Clin Infect Dis* 2000, **30**(1):100-121.
31. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR: **The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.** *Clin Infect Dis* 2000, **30**(1):122-140.
32. Falup-Pecurariu O: **Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.** *Biomedical journal* 2012, **35**(6):450-456.
33. Frenck RW, Jr., Yeh S: **The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.** *Expert Opin Biol Ther* 2012, **12**(1):63-77.

34. Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC *et al*: **A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years.** *Vaccine* 2011, **29**(32):5195-5202.
35. Moberley S, Holden J, Tatham DP, Andrews RM: **Vaccines for preventing pneumococcal infection in adults.** *Cochrane Database Syst Rev* 2013, **2013**(1):CD000422.
36. Aliberti S, Mantero M, Mirsaeidi M, Blasi F: **The role of vaccination in preventing pneumococcal disease in adults.** *Clin Microbiol Infect* 2014, **20** Suppl 5(0 5):52-58.
37. Pollard AJ, Perrett KP, Beverley PC: **Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.** *Nat Rev Immunol* 2009, **9**(3):213-220.
38. Ortiz JR, Perut M, Dumolard L, Wijesinghe PR, Jorgensen P, Ropero AM, Danovaro-Holliday MC, Heffelfinger JD, Tevi-Benissan C, Teleb NA *et al*: **A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization.** *Vaccine* 2016, **34**(45):5400-5405.
39. **European Pneumococcal Vaccination. A progress report.** <https://pneumoniaatlas.org/#map-tabs>|1 (letöltve: 2024 október 23-án) 2023.
40. **Az Országos Epidemiológiai Központ Módszertani levele a 2014. évi védőoltásokról.** *Epinfo* 2014, **21**:6-7.
41. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM *et al*: **Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.** *JAMA* 2005, **294**(16):2043-2051.
42. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S *et al*: **Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis.** *J Autoimmun* 2017, **80**:10-27.
43. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B: **Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age.** *Vaccine* 2014, **32**(20):2364-2374.
44. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T: **Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).** *MMWR Morb Mortal Wkly Rep* 2015, **64**(34):944-947.
45. Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B: **Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.** *AIDS* 2015, **29**(11):1345-1354.
46. Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A: **Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.** *PLoS One* 2014, **9**(12):e114966.
47. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P: **Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established**

- arthritis, but not those treated with tumor necrosis factor inhibitors. *Arthritis Rheum* 2011, **63**(12):3723-3732.
48. Nagel J, Geborek P, Saxne T, Jonsson G, Englund M, Petersson IF, Nilsson JA, Truedsson L, Kapetanovic MC: **The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.** *Arthritis Res Ther* 2015, **17**(1):124.
 49. Roseman C, Truedsson L, Kapetanovic MC: **The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis.** *Arthritis Res Ther* 2012, **14**(4):R170.
 50. Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P: **Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.** *Arthritis Res Ther* 2013, **15**(5):R171.
 51. Coronaviridae Study Group of the International Committee on Taxonomy of V: **The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.** *Nat Microbiol* 2020, **5**(4):536-544.
 52. Plotkin S: **History of vaccination.** *Proc Natl Acad Sci U S A* 2014, **111**(34):12283-12287.
 53. **FDA Approves First COVID-19 Vaccine.** <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine> 2021.
 54. **Plan of Tasks Related to COVID-19 Vaccination.** <http://koronavirus.gov.hu> 2021.
 55. Traynor K: **FDA approves tofacitinib for rheumatoid arthritis.** *Am J Health Syst Pharm* 2012, **69**(24):2120.
 56. **Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines.** <https://www.ecdc.europa.eu/en/news-events/updated-ecdc-ema-statement-additional-booster-doses-covid-19-vaccines> 2021.
 57. Kiss Z, Wittmann I, Polivka L, Surjan G, Surjan O, Barcza Z, Molnar GA, Nagy D, Muller V, Bogos K *et al*: **Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).** *Front Immunol* 2022, **13**:905585.
 58. Voko Z, Kiss Z, Surjan G, Surjan O, Barcza Z, Wittmann I, Molnar GA, Nagy D, Muller V, Bogos K *et al*: **Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).** *Front Immunol* 2022, **13**:919408.
 59. Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, Tarifi A, Al-Tamimi M, Al-Shudifat AE, Alsmadi H *et al*: **Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers.** *Vaccines* 2021, **9**(11).
 60. Moghnieh R, Mekdashi R, El-Hassan S, Abdallah D, Jisr T, Bader M, Jizi I, Sayegh MH, Rahman Bizri A: **Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.** *Vaccine* 2021, **39**(46):6713-6719.
 61. Farid E, Herrera-Urbe J, Stevenson NJ: **The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.** *Front Immunol* 2022, **13**:817597.

62. Park S, Gatchalian KK, Oh H: **Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.** *Cureus* 2022, **14**(7):e27323.
63. Vargas-Herrera N, Fernandez-Navarro M, Cabezudo NE, Soto-Becerra P, Solis-Sanchez G, Escobar-Agreda S, Silva-Valencia J, Pampa-Espinoza L, Bado-Perez R, Solari L *et al*: **Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.** *PLoS One* 2022, **17**(10):e0268419.
64. Nagy B, Jr.: **Foreword: Current Laboratory Aspects of COVID-19.** *EJIFCC* 2022, **33**(2):75-78.
65. Boshku AA, Aleksovski V, Tofoski G, Spasova R: **Kinetics of Antibody Response to Repeated Vaccination with Sputnik V: A Pilot Study with a Series of Five Cases.** *EJIFCC* 2022, **33**(2):175-186.
66. Fodor E, Olmos Calvo I, Kuten-Pella O, Hamar E, Bukva M, Madar A, Hornyak I, Hinsenkamp A, Hetenyi R, Foldes F *et al*: **Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.** *Eur Rev Med Pharmacol Sci* 2022, **26**(14):5297-5306.
67. Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA, Laboratorio SeVa G, Mazzitelli I *et al*: **Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.** *Cell Rep Med* 2022, **3**(8):100706.
68. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z *et al*: **Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.** *Lancet Infect Dis* 2021, **21**(1):39-51.
69. Aijaz J, Hussain S, Naseer F, Kanani F, Anis S, Sarfaraz S, Saeed S, Farooq H, Jamal S: **Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population.** *Vaccines* 2022, **10**(5).
70. Gonzalez S, Olszevicki S, Gaiano A, Baino ANV, Regairaz L, Salazar M, Pesci S, Marin L, Martinez VVG, Varela T *et al*: **Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study.** *Lancet Reg Health Am* 2022, **13**:100316.
71. **Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm.** <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP> 2022.
72. Horvath JK, Ferenci T, Ferenczi A, Turi G, Rost G, Oroszi B: **Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method.** *Vaccines* 2022, **10**(11).
73. Blanco S, Spinsanti L, Javier Aguilar J, Diaz A, Elisa Rivarola M, Beranek M, Fernandez E, Mangeaud A, Salome Konigheim B, Veronica Gallego S: **Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.** *Vaccine* 2022, **40**(47):6706-6710.

74. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD *et al*: **2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.** *Ann Rheum Dis* 2010, **69**(9):1580-1588.
75. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: **Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.** *Arthritis Rheum* 1995, **38**(1):44-48.
76. Orange JS, Ballou M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M *et al*: **Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology.** *J Allergy Clin Immunol* 2012, **130**(3 Suppl):S1-24.
77. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR *et al*: **EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.** *Ann Rheum Dis* 2011, **70**(3):414-422.
78. Centers for Disease C, Prevention: **Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).** *MMWR Morb Mortal Wkly Rep* 2012, **61**(40):816-819.
79. Publication WHO: **Pneumococcal vaccines WHO position paper - 2012 - recommendations.** *Vaccine* 2012, **30**(32):4717-4718.
80. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H *et al*: **2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.** *Clin Infect Dis* 2014, **58**(3):309-318.
81. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S *et al*: **Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.** *J Cutan Med Surg* 2019, **23**(1):50-74.
82. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB: **The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.** *Semin Arthritis Rheum* 2004, **33**(4):283-288.
83. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P: **Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.** *Rheumatology (Oxford)* 2006, **45**(1):106-111.
84. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL: **Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.** *J Rheumatol* 2007, **34**(5):952-957.
85. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabo H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A *et al*: **Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.** *Inflamm Bowel Dis* 2012, **18**(6):1042-1047.

86. Kaine JL, Kivitz AJ, Birbara C, Luo AY: **Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.** *J Rheumatol* 2007, **34**(2):272-279.
87. Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK: **Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.** *J Rheumatol* 2014, **41**(4):648-657.
88. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, Matsumura R, Suematsu E, Miyamura T, Mori S *et al*: **Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate.** *Medicine (Baltimore)* 2015, **94**(52):e2184.
89. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K: **Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.** *Ann Rheum Dis* 2013, **72**(8):1362-1366.
90. Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T, Nakashima H, Akiyama A, Nishimoto N: **Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab.** *Mod Rheumatol* 2014, **24**(3):511-516.
91. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, Kozuru H, Jiuchi Y, Matsumura R, Suematsu E *et al*: **Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.** *Arthritis Res Ther* 2015, **17**:357.
92. Alten R, Bingham CO, 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC: **Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.** *BMC Musculoskelet Disord* 2016, **17**:231.
93. Bingham CO, 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, Trzaskoma B, Martin F, Agarwal S, Kelman A: **Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.** *Arthritis Rheum* 2010, **62**(1):64-74.
94. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI: **Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.** *Arthritis Res Ther* 2010, **12**(3):R111.
95. Izumi Y, Akazawa M, Akeda Y, Tohma S, Hirano F, Ideguchi H, Matsumura R, Miyamura T, Mori S, Fukui T *et al*: **The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.** *Arthritis Res Ther* 2017, **19**(1):15.
96. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L: **Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.** *Clin Rheumatol* 2011, **30**(12):1555-1561.
97. https://www.wantszhu/felso/menu/temaink/jarvany/modszertani_levelek (letöltve: 2024 november 9-én).
98. https://ogyegovhu/gyogyszeradatbazis&action=show_details&item=220078 (letöltve: 2024 november 9-én).
99. <https://www.europharm.eu/en/medicines/human/EPAR/vaxneuvance#authorisation-details> (letöltve: 2024 november 9-én).
100. <https://www.europharm.eu/en/medicines/human/EPAR/prevenar-20#authorisation-details> (letöltve: 2024 november 9-én).

101. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC *et al*: **2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases**. *Ann Rheum Dis* 2020, **79**(1):39-52.
102. Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ *et al*: **2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases**. *Arthritis Care Res (Hoboken)* 2023, **75**(3):449-464.
103. Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB: **Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate**. *Curr Opin Rheumatol* 2008, **20**(3):295-299.
104. Meroni PL, Zavaglia D, Girmenia C: **Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs**. *Clin Exp Rheumatol* 2018, **36**(2):317-328.
105. Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB: **A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis**. *J Rheumatol* 2018, **45**(6):733-744.
106. Kapetanovic MC, Nagel J, Nordstrom I, Saxne T, Geborek P, Rudin A: **Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine**. *Vaccine* 2017, **35**(6):903-908.
107. Huang C, Hsu P, Hung Y, Liao Y, Liu C, Hour C, Kao M, Tsay GJ, Hung H, Liu GY: **Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production**. *Apoptosis* 2005, **10**(4):895-907.
108. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A: **The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis**. *Vaccine* 2018, **36**(39):5832-5845.
109. Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Aeemjinda R, Khanarat N, Vichaiwattana P, Klinfueng S *et al*: **Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens**. *Int J Infect Dis* 2023, **126**:64-72.
110. Hueda-Zavaleta M, Gomez de la Torre JC, Caceres-Del Aguila JA, Muro-Rojo C, De La Cruz-Escurra N, Arenas Siles D, Minchon-Vizconde D, Copaja-Corzo C, Bardales-Silva F, Benites-Zapata VA *et al*: **Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection**. *Vaccines* 2022, **10**(4).

9.2. List of Own Publications



UNIVERSITY of
DEBRECEN

UNIVERSITY AND NATIONAL LIBRARY
UNIVERSITY OF DEBRECEN

H-4002 Egyetem tér 1, Debrecen
Phone: +3652/410-443, email: publikaciok@lib.unideb.hu

Registry number: DEENK/491/2024.PL
Subject: PhD Publication List

Candidate: Éva Rákóczi
Doctoral School: Doctoral School of Clinical Medicine
MTMT ID: 10045656

List of publications related to the dissertation

1. **Rákóczi, É.**, Magócs, G., Kovács, S., Nagy, B. J., Szűcs, G., Szekanecz, Z.: Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.
Diagnostics. 13 (3), 1-12, 2023.
DOI: <http://dx.doi.org/10.3390/diagnostics13030556>
IF: 3
2. **Rákóczi, É.**, Perge, B., Végh, E., Csomor, P., Karancsiné Pusztai, A., Szamosi, S., Bodnár, N., Szántó, S., Szűcs, G., Szekanecz, Z.: Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept.
Joint Bone Spine. 83 (6), 675-679, 2016.
DOI: <http://dx.doi.org/10.1016/j.jbspin.2015.10.017>
IF: 3.329

List of other publications

3. Lénárt, Á., Kacska, S., **Rákóczi, É.**, Balogh, E., Dávida, L., Papp, M.: Az azatioprinkezelés indukálta csontvelő-elégtelenség ritka szövődménye, a haemophagocytás lymphohistiocytosis.
Cent. Eur. J. Gastroenterol. Hepatol. 9 (1), 166-170, 2023.
4. Szekanecz, Z., Vokó, Z., Surján, O., **Rákóczi, É.**, Szamosi, S., Szűcs, G., Szekanecz, É., Müller, C., Kiss, Z.: Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals.
Front. Immunol. 14, 1-8, 2023.
DOI: <http://dx.doi.org/10.3389/fimmu.2023.1247129>
IF: 5.7
5. **Rákóczi, É.**: Fabry-és Gaucher-kór: mlkor gondoljunk ezen ritka tárolási betegségekre?
SpringMed, 2023, 84 p., 2023.





6. **Rákóczi, É.**: Lázás állapotok a klinikai gyakorlatban.
Orvostovábbk. szle Online. 2023, 21-25, 2023.
7. Vályi-Nagy, I., Uher, F., **Rákóczi, É.**, Szekanecz, Z.: Adaptive Immunity to Viruses: what Did We Learn from SARS-CoV-2 Infection?
Int. J. Mol. Sci. 23 (22), 1-13, 2022.
DOI: <http://dx.doi.org/10.3390/ijms232213951>
IF: 5.6
8. Szekanecz, Z., Balog, A., Constantin, T., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., **Rákóczi, É.**, Szamosi, S., Szűcs, G., Vályi-Nagy, I.: COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients.
Expert Rev. Mol. Med. 24, 1-8, 2022.
DOI: <http://dx.doi.org/10.1017/erm.2022.10>
IF: 6.2
9. Szekanecz, Z., Bálint, P., Balog, A., Constantin, T., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., **Rákóczi, É.**, Szamosi, S., Szűcs, G.: A COVID-19 és a reumatológia összefüggései.
Immunol. Szle. 13 (2), 4-16, 2021.
10. Szekanecz, Z., Bogos, K., Constantin, T., Fülesdi, B., Müller, V., **Rákóczi, É.**, Várkonyi, I., Vályi-Nagy, I.: Antivirális és gyulladáscsökkentő kezelési lehetőségek COVID-19-ben.
Orv. hetil. 162 (17), 643-651, 2021.
DOI: <http://dx.doi.org/10.1556/650.2021.32230>
IF: 0.707
11. **Rákóczi, É.**: Az antibiotikum kezelés alapelvei a háziorvosi gyakorlatban.
Háziorv. továbbk. szle. 26 (2), 117-120, 2021.
12. Szekanecz, Z., Bálint, P., Balog, A., Constantin, T., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., **Rákóczi, É.**, Szamosi, S., Szűcs, G.: COVID-19-ajánlások reumatológusoknak.
Magyar Reumatol. 62, 233-241, 2021.
13. Szekanecz, Z., Bálint, P., Balog, A., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., **Rákóczi, É.**, Szamosi, S., Szűcs, G., Constantin, T.: A COVID-19 immunológiai és reumatológiai vonatkozásai.
Mozgásszervi Továbbk. Szle. 3 (2), 1-13, 2020.
14. Nagy, G. G., Tudlik, Z., Gergely, L., Kónya, J., Orosi, P., **Rákóczi, É.**, Szabó, J., Várvolgyi, C., Vítális, E., Paragh, G.: A székletmikrobiota-transzplantáció technológiájának és minőségirányítási hátterének újragondolása a SARS-CoV-2 víruspandémia kapcsán.
Orv. hetil. 161 (44), 1858-1871, 2020.
DOI: <http://dx.doi.org/10.1556/650.2020.32023>
IF: 0.54





15. Szekanecz, Z., Bálint, P., Balog, A., Barta, Z., Czirják, L., Géher, P., Kovács, L., Kumánovics, G., Nagy, G., **Rákóczi, É.**, Szamosi, S., Szűcs, G., Vályi-Nagy, I., Várkonyi, I., Constantin, T.: COVID-19: a citokinviharon innen és túl...
Immunol. Szle. 12 (4), 4-14, 2020.
16. **Rákóczi, É.**: Fájdalomcsillapítás: a hőskortól napjainkig.
Háziorv. továbbk. szle. 25 (10), 792-796, 2020.
17. **Rákóczi, É.**: Infectological approach in rheumatology.
In: Rheumatology. Ed.: Szekanecz Zoltán, Szűcs Gabriella, Debreceni Egyetemi Kiadó, Debrecen, 42-47, 2020.
18. **Rákóczi, É.**: Infektológiai szemlélet a reumatológiában.
In: Reumatológia. Szerk.: Szekanecz Zoltán, Szűcs Gabriella, Debreceni Egyetemi Kiadó, Debrecen, 42-47, 2020.
19. **Rákóczi, É.**: A Fabry-kór Janus-arca.
Immunol. Szle. Különnyomat, 1-7, 2019.
20. **Rákóczi, É.**: Akut fájdalomcsillapítás az alapellátásban: fix dózisu kombinációk helye a kezelésben.
Orvostovábbk. szle. Különszám, 18-23, 2019.
21. **Rákóczi, É.**: Infekció és vakcináció.
In: Reumatológia /Szerk. Szekanecz Zoltán, Nagy György, Medicina Könyvkiadó Zrt., Budapest, 177-194, 2019.
22. **Rákóczi, É.**: Biológiai terápia autoimmun gyulladásos kórképekben: amit a családorvosnak tudnia kell.
Háziorv. Továbbk. Szle. 23, 659-663, 2018.
23. Orlos, Z., **Rákóczi, É.**, Misák, O., Lénárt, B., Ócsai, G., Kovács, I., Gorzsás, S., Kardos, L., Lampé, Z., Szilvássy, Z., Várkonyi, I.: Outbreak of anthrax in adults and adolescents: a review of nine cases in a regional teaching hospital in East Hungary.
Clin. Microbiol. Infect. 23 (1), 52-54, 2017.
DOI: <https://doi.org/10.1016/j.cmi.2015.11.023>
IF: 5.394
24. **Rákóczi, É.**, Szekanecz, Z.: Pneumococcal vaccination in autoimmune rheumatic diseases.
RMD Open. 3 (2), 1-7, 2017.
DOI: <http://dx.doi.org/10.1136/rmdopen-2017-000484>
25. **Rákóczi, É.**, Várkonyi, I.: Antibiotikum használat - jó kezekbe!
Granum. 18 (3), 15-17, 2015.
26. **Rákóczi, É.**: Autoimmun reumatológiai kórképek és vakcináció: nemzetközi evidenciák, magyarországi lehetőségek.
Immunol. Szle. 7 (4), 4-11, 2015.





27. **Rákóczi, É.:** Biológiai terápia reumatológiai kórképekben: fertőzés-kockázat-és megelőzés.
Orvostovábbk. Szle. 22 (10), 57-61, 2015.
28. Gergely, Z., **Rákóczi, É.**, Várkonyi, I.: Pneumonia - és melyik antibiotikum?
Granum. 18 (3), 18-20, 2015.
29. **Rákóczi, É.:** Vakcináció felnőttkorban: milyen feladat hárul a háziorvosra?
Háziorv. továbbk. szle. 20 (8), 518-521, 2015.
30. **Rákóczi, É.:** Védőoltások gyakorlati útmutatója autoimmun betegségben.
Autoimmun Kaleidoszkóp 1 (8), 5-9, 2015.
31. **Rákóczi, É.**, Várkonyi, I.: Antibiotikum használat - jó kezekben!
Granum. 17 (3), 5-7, 2014.
32. Bakos, I., Jancsik, V., **Rákóczi, É.:** Antibiotikum kezelés a hepatológiában.
Granum. 17 (3), 24-26, 2014.
33. Sándor, É., **Rákóczi, É.:** Antibiotikum kezelés hasmenésben? Mikor?
Granum. 17 (3), 8-10, 2014.
34. **Rákóczi, É.:** Clostridium difficile-asszociált colitis és az immunhiányos beteg: az ajánlásokon túl.
Granum. 17 (3), 15-16, 2014.
35. Misák, O., **Rákóczi, É.:** Clostridium difficile fertőzés az alapellátásban: a kritikus pontok.
Granum. 17 (3), 11-13, 2014.
36. Várkonyi, I., **Rákóczi, É.**, Misák, O., Komáromi, E., Kardos, L., Lampé, Z., Szilvássy, Z.: Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis.
Clin. Microbiol. Infect. 20 (10), 1085-1090, 2014.
DOI: <http://dx.doi.org/10.1111/1469-0691.12652>
IF: 5.768
37. **Rákóczi, É.:** Pneumococcus kontra Prevenar 13: áttörés a felnőttkori pneumoniák megelőzésében.
Granum. 17 (3), 21-23, 2014.
38. Gergely, Z., **Rákóczi, É.:** Pneumonia - és melyik antibiotikum?
Granum. 17 (3), 17-19, 2014.
39. **Rákóczi, É.**, Várkonyi, I.: Antibiotikum használat: jó kezekbe.
Granum. 16, 6-9, 2013.
40. Bakos, I., Jancsik, V., **Rákóczi, É.:** Antibiotikum kezelés a hepatológiában.
Granum. 16 (2), 21-23, 2013.
41. Sándor, É., **Rákóczi, É.:** Antibiotikum kezelés hasmenésben?
Granum. 16 (2), 24-26, 2013.





42. Misák, O., **Rákóczi, É.**: Clostridium difficile fertőzés az alapellátásban: a kritikus pontok.
Granum. 16 (2), 27-29, 2013.
43. **Rákóczi, É.**, Maródi, L.: Fiatalkori ízületi gyulladás.
In: Gyermekgyógyászat. Szerk.: Maródi László, Medicina Könyvkiadó Zrt., Budapest, 490-498, 2013.
44. **Rákóczi, É.**, Várkonyi, I., Szekanecz, Z.: Pneumococcus-fertőzések és megelőzésük: vakcinációs update reumatológiai autoimmun kórképekben.
Magyar Reumatol. 54, 176-181, 2013.
45. Gergely, Z., **Rákóczi, É.**: Pneumonia-és melyik antibiotikum?
Granum. 16 (2), 18-20, 2013.
46. **Rákóczi, É.**, Bakos, I., Sándor, É., Várkonyi, I.: Prevenar 13 konjugált védőoltás: vakcináció betegeink és mindannyiunk védelmében - új gyógyszerekről röviden.
Orvostovábbk. Szle. 10 (Különlenyomat), 85-88, 2013.
47. **Rákóczi, É.**: "Clostridium helyzet" Magyarországon, 2012.
IME. 11 (10), 20-23, 2012.
48. Szilasi, M., Mátyus, J., Kuzskáné File, I., Szűcs, G., **Rákóczi, É.**, Pfliegler, G., Szabó, Z., Végh, E., Szekanecz, Z.: Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: rituximab may be the right choice?
Autoimmunity. 45 (4), 304-309, 2012.
DOI: <http://dx.doi.org/10.3109/08916934.2012.677078>
IF: 2.767
49. **Rákóczi, É.**: Gyermekreumatológia.
In: Reumatológia. Szerk.: Szekanecz Zoltán, SpringMed Kiadó, Budapest, 193-213, 2011.
50. Harangi, M., Kovács, T., **Rákóczi, É.**, Rejtő, L., Mikó, L., Tóth, L., Szűcs, G., Galuska, L., Paragh, G.: Malignancy or inflammation?: a case report of a young man with fever of unknown origin.
Pathol. Oncol. Res. 17 (2), 409-413, 2011.
DOI: <http://dx.doi.org/10.1007/s12253-010-9315-1>
IF: 1.366
51. **Rákóczi, É.**: Antibiotikum terápia.
In: Farmakoterápia. Szerk.: Bakó Gyula, Medicina Könyvkiadó Zrt., Budapest, 297-336, 2010.
52. Constantin, T., **Rákóczi, É.**, Ponyi, A., Ambrus, C., Kádár, K., Vastagh, I., Dajnoki, A., Lajszné Tóth, B., Bokrétás, G., Müller, V., Katona, M., Csíkós, M., Fiedler, O., Széchezy, R., Varga, E., Rudas, G., Kertész, A. B., Molnár, S., Kárpáti, S., Nagy, V., Magyar, P., Mahdi, M., Németh, K., Bereczki, D., Garami, M., Erdős, M., Maródi, L., Fekete, G.: Fabry-betegség: diagnosztikai útmutató.
Orv. Hetil. 151 (7), 243-249, 2010.
DOI: <http://dx.doi.org/10.1556/OH.2010.28795>





53. Constantin, T., Székely, A., Ponyi, A., Gulácsy, V., Ambrus, C., Kádár, K., Vastagh, I., Dajnoki, A., Lajszné Tóth, B., Bokrétás, G., Müller, V., Katona, M., Medvecz, M., Fiedler, O., Szécheý, R., Varga, E., Rudas, G., Kertész, A. B., Molnár, S., Kárpáti, S., Nagy, V., Magyar, P., Mahdi, M., **Rákóczi, É.**, Németh, K., Bereczki, D., Garami, M., Erdős, M., Maródi, L., Fekete, G.: Fabry-betegség - terápiás útmutató.
Orv. Hetil. 151 (31), 1243-1251, 2010.
DOI: <http://dx.doi.org/10.1556/OH.2010.28796>
54. **Rákóczi, É.**: Antibiotikum kombinációk alkalmazása.
In: *Infekció és infekciókontroll / Ternák Gábor, Almási István, Rákóczi Éva, Szabó Judit, PTE ÁOK Nyomda, Pécs, 279-281, 2009.*
55. **Rákóczi, É.**, Lajszné Tóth, B., Görögh, S., Erdős, M., Sümegi, J., Maródi, L.: Association of renal ectopy with Fabry disease in three patients.
J. Urol. 181 (4), 1949-1954, 2009.
DOI: <http://dx.doi.org/10.1016/j.juro.2008.11.091>
IF: 4.016
56. **Rákóczi, É.**: Modern biológiai "fegyvereink".
Lege Artis Med. 19 (2), 127-131, 2009.
57. **Rákóczi, É.**: Oropharyngealis és nasalis fertőzések.
In: *Klinikai alapismeretek fogorvos-és gyógyszerész hallgatóknak. Szerk.: Boda Zoltán, Tornai István, Medicina Könyvkiadó Zrt., Budapest, 361-375, 2009.*
58. Ternák, G., Almási, I., **Rákóczi, É.**: Hospital antibiotic management in Hungary - results of the ABS maturity survey of the ABS International group.
Wien. Klin. Wochenschr. 120 (9-10), 299-302, 2008.
DOI: <http://dx.doi.org/10.1007/s00508-008-0972-y>
IF: 0.857
59. Erdős, M., Garami, M., **Rákóczi, É.**, Zalatnai, A., Steinbach, D., Baumann, U., Kropshofer, G., Lajszné Tóth, B., Maródi, L.: Neuroendocrine carcinoma associated with X-linked hyperimmunoglobulin M syndrome: report of four cases and review of the literature.
Clin. Immunol. 129 (3), 455-461, 2008.
DOI: <http://dx.doi.org/10.1016/j.clim.2008.08.005>
IF: 3.606
60. Jiao, H., Lajszné Tóth, B., Erdős, M., Fransson, I., **Rákóczi, É.**, Balogh, I., Magyarics, Z., Dérfalvy, B., Csorba, G. É., Szaflarska, A., Megarbane, A., Akatcherian, C., Dbaibo, G., Rajnavölgyi, É., Hammarström, L., Kere, J., Lefranc, G., Maródi, L.: Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups.
Mol. Immunol. 46 (1), 202-206, 2008.
DOI: <http://dx.doi.org/10.1016/j.molimm.2008.07.001>
IF: 3.555





61. Erdős, M., Németh, K., Lajszné Tóth, B., Constantin, T., **Rákóczi, É.**, Ponyi, A., Dajnoki, A., Grubits, J., Pintér, I., Garzuly, F., Hahn, K., Bencsik, K., Vécsei, L., Fekete, G., Maródi, L.: Novel sequence variants of the alfa-galactosidase A gene in patients with Fabry disease. *Mol. Genet. Metab.* 95 (4), 224-228, 2008.
DOI: <http://dx.doi.org/10.1016/j.ymgme.2008.09.002>
IF: 2.629
62. **Rákóczi, É.**, Görögh, S., Grubits, J., Erdős, M., Garzuly, F., Hahn, K., Bencsik, K., Vécsei, L., Trinn, C., Kristóf, É., Mogorósy, G., Lajszné Tóth, B., Maródi, L.: A Fabry-kór molekuláris patológiája és klinikai megjelenési formái. *Orv. Hetil.* 148 (23), 1087-1094, 2007.
DOI: <http://dx.doi.org/10.1556/OH.2007.28086>
63. **Rákóczi, É.**: Gyógyszerinterakciók antibiotikumok alkalmazása során. *Stud. Pract.* 1 (6), 14-16, 2007.
64. Erdős, M., Alapi, K., Balogh, I., Oroszlán, G., **Rákóczi, É.**, Sümegi, J., Maródi, L.: Severe Shwachman-Diamond syndrome phenotype caused by compound heterozygous missense mutations in the SBDS gene. *Exp. Hematol.* 34 (11), 1517-1521, 2006.
DOI: <http://dx.doi.org/10.1016/j.exphem.2006.06.009>
IF: 3.408
65. **Rákóczi, É.**, Pfliegler, G., Maródi, L.: A diagnosztika útvesztői Fabry-kórban. *Háziorv. Továbbk. Szle.* 10 (2), 147-149, 2005.
66. **Rákóczi, É.**, Maródi, L.: Az Epstein-Barr-vírus okozta fertőzések immunpatológiája. *Gyermekgyógyászat.* 56 (2), 141-145, 2005.
67. Erdős, M., Uzvölgyi, É., Nemes, Z., Török, O., **Rákóczi, É.**, Went, S. N., Sümegi, J., Maródi, L.: Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. *Hum. Mutat.* 25 (5), 506, 2005.
DOI: <http://dx.doi.org/10.1002/humu.9339>
IF: 7.923
68. **Rákóczi, É.**, Borbély, Á., Fekete, A., Szabó, J.: Nosocomialis pneumonia Magyarországon: klinikai és mikrobiológiai aspektus. *Anaesthesiol. Intenzív Ther.* 35 (4), 16-33, 2005.
69. **Rákóczi, É.**, Erdős, M., Bartyik, K., Kemény, É., Nemes, Z., Maródi, L.: X-kromoszómához kötött lymphoproliferatív betegség. *Gyermekgyógyászat.* 55 (2), 27-30, 2004.





**UNIVERSITY of
DEBRECEN**

**UNIVERSITY AND NATIONAL LIBRARY
UNIVERSITY OF DEBRECEN**

H-4002 Egyetem tér 1, Debrecen
Phone: +3652/410-443, email: publikaciok@lib.unideb.hu

70. **Rákóczi, É.**, Magócs, G., Princzinger, Á., Dicső, F.: Az epilepszia immunológiai vonatkozásai.
Gyermekgyógy. 54 (2), 143-147, 2003.

Total IF of journals (all publications): 66,365

Total IF of journals (publications related to the dissertation): 6,329

The Candidate's publication data submitted to the iDEa Tudóstér have been validated by DEENK on the basis of the Journal Citation Report (Impact Factor) database.

24 September, 2024



10. Keywords - Tárgyszavak

- Antibody response, autoimmune rheumatologic diseases, BBIBP-CorV, biologic therapy, BNT162b2, conjugated vaccine, etanercept, heterologous vaccination, homologous vaccination, immunocompromised, immunogenicity, pneumococcal infections, pneumococcal vaccine, pneumonia, Prevenar 13, rheumatoid arthritis, SARS-CoV-2
- antitest válasz, autoimmun reumatológiai betegségek, BBIBP-CorV, biológiai terápia, BNT162b2, konjugált vakcina, etanercept, heterológ oltás, homológ oltás, immunhiányos állapot, immunogenitás, pneumococcus fertőzések, pneumococcus vakcina, pneumonia, Prevenar 13, reumatoid artritis, SARS-CoV-2

11. Acknowledgements

I would like to express my deep gratitude to **Professor Zoltán Szekanecz** my research supervisor for supporting this special topic and for being an excellent motivating mentor. I am grateful for his continuous open-minded support, and encouragement throughout my whole clinical work at the university and my PhD.

My special thanks are extended to **Professor Gabriella Szűcs** the clinical director of **Division of Rheumatology** and all division's staff for the excellent help and valuable contribution in my clinical research.

I am grateful to **Professor László Maródi**, who drew my attention to the special connection between infection and immunity.

I wish to thank **Dr Bianka Perge MD** and **Sára Kovács**, for **Dr Gusztáv Magócs** General Practitioner and **his staff** for the assistance in administering vaccination; the staff of **Vamospercs Outpatient Clinic** for their help in control group selection.

I would like to express my gratitude to **Dr Bela Nagy** and **his staff** for excellent laboratory tests and analysis and to **Ms Katalin Hodosi** and **Zsolt Karányi** for the statistical analysis.

I am thankful to **all the patients** who participated in the studies.

I would like to thank **Dr Mohamed Mahdi** for the language correction.

Finally, I would like to thank **my family**, my husband **Gusztáv** and my children, **Dávid, Éva and Ádám** for their patience and love.

12. Appendix

Publications Underlying the Dissertation